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Doxorubicin is one of the most versatile cytostatic drugs available and shows efficacy on most 
cancer forms. However, it also possesses the risk of cardiotoxicity that is hard to predict, can 
occur decades after treatment, and that limits the cumulative lifetime doses of the drug. Various 
approaches have been tested to avoid this toxicity, with liposomal forms of doxorubicin already 
being on the market. Additionally, some studies have shown that statins can limit doxorubicin 
induced cardiotoxicity, and also improve the anti-cancer effects of the drug.  
 
The zebrafish has over the last decades emerged as a convenient and relevant model for human 
cancer research. The species has rapid development, the skin is optically transparent, their 
genome is comparable to that of humans, and they enable for very easy in vivo imaging. In this 
study zebrafish larvae were used to study the potential cardioprotective effect of simvastatin in 
co-treatment with doxorubicin, as well as how liposomal formulations of these drugs influence 
heart function. Moreover, the zebrafish larvae were tested as a model organism for cancer.  
 
Doxorubicin was loaded into liposomes with or without simvastatin incorporated into the lipid 
bilayer and tested in in vitro cytotoxicity assays on H9C2 cardiomyoblast cells and MCF-7 
breast cancer cells and in vivo in zebrafish larvae. Additionally, fluorescently stained MCF-7 
cells were injected in zebrafish larvae and observed over two days. 
 
In the zebrafish larvae injected with fluorescent MCF-7 cells in the yolk sac, the fluorescent 
signal was observed to spread to the tail of the zebrafish larvae after one- and two-days post 
injection and to increase in number and size. More experiments need to be conducted to verify 
this being viable MCF-7 cells.  
 
Liposomal forms of doxorubicin were found to have less impact on zebrafish heart rate, death 
and pericardial edema and resulted in increased viability in the cytotoxicity assays compared to 
free doxorubicin. Co-loading with simvastatin did not give an observed additional 
cardioprotective effect in zebrafish larvae. In the in vitro studies, however, free simvastatin co-
therapy with high-doses of free doxorubicin contributed to increased viability of H9C2 
cardiomyoblast cells relative to free doxorubicin alone, while no such effect was observed for 
the MCF-7 breast cancer cells. The zebrafish larvae allow for direct observations of 
physiological functions in an intact, living organism, while still being an inexpensive model. 
Therefore, zebrafish larvae prove superior to cell cytotoxicity models in the study of  toxicity 






2.1 Cancer and Cancer Therapies 
Cancer is a group of diseases caused by abnormal cells dividing uncontrollably in the body, 
commonly forming tumors and invading other tissue. Today, approximately one in six deaths 
worldwide is due to cancers (1). Cancer occur in one of three people, and are commonly treated 
by surgery, drug therapy or radiation. Drug therapies are traditionally chemotherapy, but may 
also involve hormone therapy, and an increasing amount of biological compounds and 
immunotherapy are being used (2). Biological compounds can be monoclonal antibodies 
directed towards antigens on the cancer cell surface. With these it has become possible to 
specifically attack cancer cells, thereby lowering the toxicity in normal tissue and increasing 
the efficiency (3). Recent advances in immunotherapy also involves modifications of patient T-
cells to recognize tumor specific antigens (4). Difficulties in finding tumor specific antigens 
and the heterogenicity in cancers however, often minimize the advantages of these drugs (3). 
Because the new, biological compounds is limited in many cases, modifying anti-cancer drugs 
already on the market can be a solution in the cancer drug discovery process. 
 
Most anti-cancer treatments give adverse and toxic effects during treatment, as well as 
protracted effects which can occur years after recovery from cancer (5). The maximum tolerated 
dose (MTD) of a drug is the highest possible dose a patient can receive, without experiencing 
unacceptable toxicity (6). MTD is determined in phase I trials, and in cancer, because of the 
high lethality, quite extensive adverse effects, such as fatigue, nausea and vomiting, anaemia 
and infections will be tolerated (7, 8). Chemotherapy is particularly challenging because the 
target in cancer therapy is our own diseased cells, which are difficult to distinguish from normal 
cells. This can also lead to severe toxic effects on healthy tissue, and in some cases even death 
(9). Thus, there is a need for new and efficient treatments causing less side-effects.  
 
During the early phases of anti-cancer drug development, cell models are often used to find 
efficacy and possible unwanted effects of lead compounds. In vitro cell assays can give 
indications of cytotoxic activity, and high throughput screenings of thousands of substances can 
easily be conducted at a low cost (10). The models make it possible to directly visualize cell 
processes of tumor development. However, cell lines do not represent the heterogeneity of a 
tumor and lack the ability to model the complete tumor microenvironment (11). More advanced 





the in vivo situations, but cannot replicate the organs and tissues working together in an animal 
(12). Animal models, while being much more similar to humans, often lack the properties of 
easy cancer visualization, are time consuming, and expensive (11). The high cost and long time 
for preclinical mammalian trials limits the number of compounds that can be tested in vivo. 
However, in vivo testing in mammals is a requirement for drugs to ensure safety of drugs for 
human and veterinary use (13). Intermediary animal models prior to testing on mammals, could 
make it possible to inexpensively do larger in vivo screenings and tests to further increase safety 
and efficacy of new drugs.  
 
2.2 Anthracyclines 
Anthracyclines were first extracted from the actinobacteria Streptomyces peucetius and belong 
to the group of cytotoxic antibiotics (14). The main mechanisms of action for the drugs are 
intercalation in the deoxyribonucleic acid (DNA)-helix preventing both synthesis of ribonucleic 
acid (RNA) and DNA, and inhibition of the protein Topoisomerase II which is essential in DNA 
replication and protein synthesis (2). The most used anthracyclines are doxorubicin (DOX), 
daunorubicin (DNR), epirubicin (EPI) and idarubicin (IDA) (15), where EPI and IDA, are 
derivatives of DOX and DNR, respectively (16). The drugs are quite similar but contain small 
molecular differences in their chemical structure (Figure 2.1). DOX is one of the most 
commonly used cytostatic drugs, with only a few cancer types being unresponsive. The drug is 
for instance used in treating acute lymphatic leukemias in children and adults, and breast cancer 
(17-19). DOX and EPI are similar in dose-response relationships. However, EPI has shown a 
lower cardiotoxic risk at high-dose therapy (20, 21). DNR and IDA are both used in the 
treatment of leukemias (22, 23). The efficiency of the two drugs varies based on cancer, patient 
and tumor, but they have similar profiles in adverse effect and toxicity (24, 25). In this study, 
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Figure 2.1: Chemical structures of the anthracyclines. From the left, doxorubicin (DOX, A), 
daunorubicin (DNR, B), epirubicin (EPI, C) and idarubicin (IDA, D). In DOX there is an 
alcohol group connected to the ketone on ring 4, which is absent in DNR. IDA is a derivate of 
DNR and lacks the methoxy group on ring 1. The difference between DOX and EPI is an R/S 
conversion of the alcohol group on the sugar connected to ring 4.  
 
One of the biggest disadvantages with the anthracyclines, in particular DOX, is the cardiotoxic 
adverse effects (26). The cardiotoxic effects can be both acute and chronic. Acute cardiotoxic 
effects occur during or after the first days of treatment and are often reversible changes. These 
could for instance be arrythmias and nonspecific electrocardiogram changes like lowered QRS-
T voltage, ST-segment depression and premature ventricular heartbeats (27, 28). Acute 
cardiotoxic effects occur in approximately 11% of patients receiving DOX (28). Chronic 
anthracycline cardiomyopathy, however, is hard to predict during treatment and causes all 
anthracyclines to have recommended restrictions in their cumulative lifetime dosage (15). The 
effects are dose related, and a retrospective study including three trials found an estimated 
increase of congestive heart failure from 5% to 48% of patients receiving a cumulative DOX 
dose of 400 mg/m2 and 700 mg/m2, respectively (29). Apart from cumulative dose, several risk 
factors for cardiotoxic effects are reported such as old age, young age (children), previous 
cardiovascular disease (CVD), and ethnicity (30). Chronic DOX cardiomyopathy can lead to 
congestive heart failure and death (26). 
 
The mechanism for anthracycline cardiotoxicity is not fully understood, but there are several 
possible explanations. One of the main theories is by the generation of reactive oxygen species 
(ROS) (31). While anthracyclines inhibit topoisomerase IIa in cancer cells, they also inhibit 
topoisomerase IIb in cardiomyocytes. This can cause double stranded DNA breaks and a 
possible accumulation of ROS, leading to cardiomyocyte injury and death (32). Anthracyclines 
is also shown to give both physical and functional damage to mitochondria like swelling of the 
mitochondria and is also found to interfere in the electron transport chain in the energy 
metabolism processes in cells in vitro. However, in vivo it is observed that the effect on energy 
metabolism continue after removal of the drug, indicating that other components than 
interference with the electron transport chain must be affected (33). The drugs also have high 





The complex created between anthracyclines and cardiolipin ultimately leads to a 
overproduction of ROS, and following damage of the cardiomyocytes (34).   
 
To summarize, cancer therapies are often treatments with many adverse effect and high toxicity, 
and there is a constant need for new, more effective, less toxic drugs. DOX is a cytostatic with 
effect on most cancer types, but still inhabits a risk of chronic cardiomyopathy in many patients. 
As this already is an effective cytostatic agent, an attractive approach is to reduce its 
cardiotoxicity and improve patient safety. In the following sections, both the use of statins and 
nanosized drug delivery systems (NDDS) will be discussed as possible protective mechanisms 
in anthracycline therapy.  
 
2.2.1 Statins as a Cardioprotectant in Anthracycline Therapy 
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, commonly known 
and further referred to as statins, are drugs used in the treatment of hyperlipidemia. The drugs 
are inhibitors of the enzyme HMG-CoA reductase which reduces HMG-CoA to mevalonate, a 
rate limiting step in the cholesterol synthesis (2). Statins resultingly gives a decrease in low 
density lipoprotein (LDL)-cholesterol, which are atherogenic particles. The impaired 
cholesterol synthesis decreases intracellular cholesterol in the liver, causing higher numbers of 
liver LDL-receptors, increasing uptake, thus further lowers the LDL-cholesterol in the blood. 
At the same time there is a reduction in total triglycerides and a rise in high density lipoproteins 
(HDL). HDL transport cholesterol away from the arteries and are not atherogenic, and 
considered beneficial to prevent CVD (35).  
 
The statins are a widely used drug group. In 2019 more than ten percent of the Norwegian 
population were prescribed a statin, and 3.3 percent were prescribed simvastatin (SIM), 
according to the Norwegian prescription register (36). The drugs have been in use for decades, 
and protect against CVD by preventing the formation of atherosclerotic plaque and clotting of 
the coronary arteries (37).The half-life of SIM is approximately five hours, causing the drug to 
preferably be administrated in the evening to inhibit cholesterol synthesis, which peaks early in 
the morning (2). SIM is a prodrug, and after absorption, the lactone ring of SIM is hydrolyzed 
in the liver to yield the active component (see Figure 2.2 for chemical structure of the prodrug 
and the active form of SIM) (38, 39). SIM undergoes high first pass hepatic metabolism, and 





commonly used as prodrugs to increase lipophilicity and membrane permeability of drugs (40). 
However, for SIM, because of the high first pass metabolism in the liver, which also is the 
primary cite of action for SIM, the prodrug show higher tissue selectivity as prodrug than the 
drug administered in active form (38). 
 
 
Figure 2.2: Conversion of simvastatin (SIM) into active drug. The chemical structure of SIM 
as prodrug (left) and the hydrolyzed form of the drug after enzymatic conversion in the body. 
Hydrolyzation opens the lactone ring and yields the active form which is a lipid lowering drug 
(38). 
In addition to the cholesterol lowering effects, statins are shown to possess several other actions 
unrelated to LDL-lowering effects, so-called pleiotropic effects. The effects are both related 
and unrelated to the inhibition of HMG-CoA reductase and include improved endothelial 
function, decreased inflammation in vascular tissue, antithrombotic effects and more (2, 31, 
41). As mentioned above, statins reduce the risk of CVD. Additionally, statins are shown to 
reduce cardiotoxic effects of anthracyclines, and are being increasingly explored as 
cardiovascular protectants in anthracycline therapy (31). One murine study also found the use 
of the statin lovastatin to improve the anti-cancer effects of doxorubicin, while still reducing 
the cardiotoxicity (42). The pleiotropic effect of statins may play a part in the cardioprotective 
effect statins show in anthracycline therapy (31). 
 
2.3 Nanosized Drug Delivery Systems (NDDS) 
The word “nano” comes from Greek, and in science the word referrers to a billionth of a base 
unit and consequently, the size scales in nanotechnology are within billionth of a meter, 
nanometers (43). In order to be valid as nanosized, 50% or more of the particles must have one 




















Commission (44). NDDS are one of the strategies that are being extensively studied to 
overcome challenges in cancer therapy by reformulating existing, effective cytostatic drugs. 
Nanoparticles are able to carry drugs, and possess abilities which can alter the pharmacokinetic 
properties, reduce toxic effects and target desired tissue (45).  
 
NDDS can be derived from several different materials giving rise to nanoparticles with distinct 
properties regarding size, drug loading, efficiency and biocompatibility, to mention a few (46). 
Materials made to create nanoparticles in medicine can be polymers, dendrimers and lipid based 
such as micelles or liposomes and many more (46, 47). There are several reasons for utilizing 
NDDS to transport drugs in the body. Nanoparticles can increase solubility of hydrophobic 
drugs or extend half-life of drugs that are easily eliminated from the body, resulting in a larger 
area under the curve (2). By increasing the solubility of drugs when using nanoparticles, higher 
amounts of drug can be delivered by injection without using potential harmful solvents (48). 
Examples of some toxic solvents are dimethyl sulfoxide (DMSO), which is often used as a 
solvent in cell assays, and Cremophor EL, a vehicle used to deliver the cytostatic drug paclitaxel 
and is known to cause several adverse effects, including anaphylactic reactions in some patients 
(48, 49). In the case of paclitaxel the use of nanoparticle albumin, which is a natural protein 
and carrier of hydrophobic compounds in the body, became a solution to avoid the toxic effects 
of Cremophor EL (50). Nanoparticles can be modified to further increase drug circulation. One 
common approach is to attach hydrophilic polymers onto the liposome surface of liposome drug 
carriers. Polymers such as polyethylene glycol (PEG), illustrated in Figure 2.3, will mask the 
exogenous liposomes from being cleared by the reticuloendothelial system (51). However, 
perhaps most importantly, NDDS are used to decrease drug toxicity (52).  
 
By increasing target specificity NDDS can be used to reduce adverse or toxic effects (53, 54). 
This has already been demonstrated in the liposomal formulation of DOX, marketed as Doxil® 
(or Caelyx®). This FDA-approved formulation shows less cardiotoxic effects compared to free 
DOX (55). A description of the cardioprotective effects of liposomal anthracyclines is given in 
section 2.3.1. NDDS are also explored to direct the cells by passive or active targeting, thereby 
minimize exposure to non-cancerous tissues. Passive targeting takes advantage of the enhanced 
permeability and retention effect. This is a phenomenon arising when a growing tumor has an 
increasing need for oxygen and nutrients, and the developing neovasculature inside the tumor 





integrity between the endothelial cells, which makes it leaky (56). This causes accumulation of 
macromolecular compounds such as proteins, as well as nanoparticles at the tumor site (56). 
Active targeting of nanoparticles can be achieved by attaching molecules onto the nanoparticle 
surface, which for instance has affinity towards molecules on cancer cells or tumor vasculature 
(52). 
 
2.3.1 Liposomal Formulation of Anthracyclines 
As mentioned, liposomes are already used in the clinic as a NDDS, and because of their high 
biocompatibility they are the starting point for many NDDS (57). Liposomes consist of a lipid 
bilayer surrounding an aqueous compartment with the possibility to entrap hydrophilic drugs 
in the aqueous core and lipophilic molecules in the lipid bilayer (Figure 2.3) (58).  
 
 
Figure 2.3: Liposome structure. Liposomes consist of lipid bilayers and can be multilamellar, 
having multiple lipid bilayers (A) and unilamellar liposomes with only one lipid bilayer (B). 
The liposomes can be modified by adding hydrophilic polymers to the outer lipid layer or 
targeting groups to increase favorable pharmacokinetic properties. Drugs or other desired 
compounds can be trapped inside the aqueous phase, inside the lipid bilayer or adhered to the 
outside of the liposomes (C). Figure modified from Aulton’s Pharmaceutics: The Design and 
Manufacture of Medicines, fifth edition (59) and Singh et al. (52). 
Loading of DOX into liposomes can be achieved passively by utilizing a pH gradient whereby 
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the membrane. Once inside the liposomes the DOX molecules becomes protonated in the more 
acidic environment and the positively charged molecule is unable to diffuse back through the 
membrane (Figure 2.4) (60). The main goal of liposomal DOX is to reduce toxic side effects 
associated with DOX treatment (61).  
 
 
Figure 2.4: Doxorubicin (DOX) encapsulation in liposomes. Unionized DOX diffuses into the 
liposome and becomes ionized at the amine site with pKa 8.15 (40) when introduced to pH 6 
inside the liposomes (red circle), preventing the DOX molecules from diffusing back out 
through the membrane.  
2.4 Zebrafish as a Research Model for Human Cancer 
Zebrafish (Danio rerio) has the last decades emerged as an important model to study several 
human diseases and in toxicology research (62, 63). Approximately 70% of the human genome 
has a zebrafish ortholog, and even epigenetic features are conserved between at orthologous 
genes (64, 65). The cost of keeping zebrafish is much lower than for small mammals, while still 
making it possible to observe physiological processes that cannot be achieved when using cells 
assays (62). Not only the adult zebrafish is used in cancer research. Although not fully 
developed, the zebrafish larvae have properties making them attractive research models. 
Zebrafish larvae can be exposed to drugs in embryo water, as they absorb small molecules 
through the epithelium but drugs can also be administered by injection into the larvae (66). 
Additionally, the juvenile larvae does not have a developed adaptive immune system, making 
them attractive as transplantation models (67). The zebrafish can become an important 























new drugs after cell assays, making it possible to increase the number of in vivo tests on new 
lead compounds.  
 
Besides it being a relevant model for human diseases such as cancer (section 2.4.2), in research 
of CVD, kidney disorders, central nervous system disorders, muscle disorders and many more 
(68, 69), the zebrafish is advantageous due to its rapid embryonic development, and that it easily 
produces between 100-200 eggs per week (70). The zebrafish embryo hatches sporadically 
between 48 to 72 hours post fertilization (hpf), and not at a specific developmental stage, but 
the embryos can also develop outside their chorion from 24 hpf without it affecting survival 
(71-73). The high number of embryos and rate of hatching gives a possibility for higher 
throughput, while lowering husbandry requirements, time and expenses compared to studies on 
small mammals. Zebrafish do not require feeding until five days post fertilization (dpf), and 
prior to this they receive all their nutrition from the yolk sac (74). Larval forms of vertebrates 
are not considered laboratory animals until they are independently feeding (Directive 
2010/63/EU of the European parliament and council), and until five dpf the embryo and larvae 
allow for very inexpensive in vivo studies (75).  
 
Altering the zebrafish genome has become increasingly popular, and many different gene 
modified zebrafish strains exist (76). These strains can inhabit a range of specific phenotypes 
such as lack of pigmentations (see paragraphs below), fluorescent tissues, or mutated to 
spontaneously generate cancers (See section 2.4.2) (77). The ability to genetically modify 
zebrafish has made it even more relevant in cancer research as cell functions can be observed 
in a microscope in an intact organism. The zebrafish larvae are optically transparent until 
approximately 24 hours post fertilization (hpf), when it starts developing pigmentation (78). By 
adding the chemical 1-phenyl 2-thiourea (PTU) in the embryo water, however, pigmentation 
can be stopped. PTU inhibits the formation of melanophores but does not reverse pigmentation, 
and treatment must start prior to pigmentation formation, and continue for as long as optical 
transparency is desired since the process is reversible at withdrawal of the chemical (78). 
However, the development of strains that are pigment free throughout life has been important 
for observation of physiological and cellular processes in vivo inside the zebrafish.  
 
The casper strain was created by breeding two recessive pigment mutants, nacre and roy 





of melanocytes in the nacre strain is due to a mutation in the mitfa gene, while roy orbison 
harbor a mutation in the mpv17 gene. The resulting casper fish is optically transparent 
throughout adulthood (79). Figure 2.5 show images of AB wild type strain, roy orbison and 
casper zebrafish strains as larvae and adult.  
 
 
Figure 2.5: Pigmentation of zebrafish strains. The images (top to bottom) show the AB wild 
type strain, roy orbison strain which lack reflective iridophores, and casper strain lacking 
iridophores and melanocytes as larval (left) and adult fish (right). The casper strain is a result 
of breeding roy orbison and the nacre strain, the latter lacking melanocytes, leaving casper 
optically transparent. Figure obtained from D’agati et.al. (79). Not to scale.  
2.4.1 Zebrafish in Drug Development 
Testing potential drugs on mammals is a requirement in drug development but using zebrafish 
as a screening tool or as an additional animal model can prove useful. Testing potential drugs 
and chemicals on zebrafish have shown great potential and have already proven successful in 
multiple cases (80). One example is the prostaglandin E2 derivative 16,16-dimethyl 
prostaglandin E2, also referred to as FT1050, which was discovered in a zebrafish larvae 
screening with 2,500 compounds. This drug entered phase two clinical trials under the name 
ProHema-CB in 2013 (81, 82). Drug screening using thousands of zebrafish larvae is easy and 
affordable. Characterization of liver enzymes in zebrafish has also indicated that they 
metabolize drugs similar to humans. A total of 93 Cytochrome P450 enzymes (CYPs) have 
been found in adult zebrafish. CYPs transform several compounds in the body including 
inactivation and activation of drugs and prodrugs. Many of the enzymes found in zebrafish are 
orthologs to human CYPs, and likely also have conserved mechanisms. A majority of these 






2.4.2 Zebrafish as a Cancer Model 
The use of zebrafish in cancer research have advanced after a study from 1965 where zebrafish 
neoplasms were found to evolve following the exposure carcinogens (84). Zebrafish have 
several advantages in cancer research. As mentioned, they have relatively high genetically 
equivalence to humans, are fast developing and require low husbandry costs, making the species 
an attractive research model (85). Zebrafish cancer models can be created either by 
transplantation or as genetically engineered zebrafish to spontaneously develop cancers (86). 
 
Inducing cancers in zebrafish serve the purpose of observing the cancer from the cell of origin, 
and to study the cancer initiation and tumor progression processes. By observing evolving 
cancers in zebrafish it is also possible to identify genes involved in the cancer process to 
discover possible drug targets (86). The transgenic models can be achieved by chemical 
mutagenesis by exposing the fish to known carcinogens, by irradiation or by using transgenic 
tools (62). Exposure to carcinogens and irradiation will cause random mutation, but several 
transgenic tools are now available to create desired mutations regulated both spatially and 
temporally in the zebrafish (87). As zebrafish possess most of the tissues and organs as 
mammals apart from some exceptions like lungs and mammary tissue, most cancers can be 
expressed or mimicked in zebrafish (86). Through observing the initial processes in tumor 
progression and initiation there are great possibilities to discover the roles of specific genes in 
cancer processes to identify potential drug targets.  
 
The second way to achieve cancer in zebrafish is by transplantation of cells or tissue. Zebrafish 
has the advantage of not possessing an adaptive immune system until about three weeks post 
fertilization, and will prior to this not reject transplanted tumor cells or tissue (67). Adult fish 
have an adaptive immune system, but treatment with either radiation or dexamethasone can 
suppress the immune system and prevent rejection of transplants (85). These methods allow for 
easy and affordable in vivo cancer models. For long term studies syngeneic zebrafish clones 
makes transplantation possible. In this way a cancer induced in one fish can be transplanted 
into a syngeneic fish without the risk of transplant rejection. The transplanted fish can have a 
fully developed and active immune system, which makes it possible to observe how immune 






Studying cancers in vivo inside the zebrafish enables us to observe cancer activities such as 
migration, metastasis, tumor angiogenesis and how this can be genetically altered. 
Manipulation of the zebrafish genome to obtain fluorescent endothelium, has made it possible 
to visualize tumor angiogenesis after cancer cell transplantations (89). By using fluorescent 
cancer cells for transplantation, either by genetic approaches or by cell staining, the cells can 
be monitored over time inside zebrafish. In this study a xenograft approach will be made by 
transferring cancer cells into zebrafish larvae and observing the movement and development of 
these cells over time inside the larva.  
 
2.5 Aims 
As many drugs are withdrawn from clinical studies and the market after the discovery of 
cardiotoxic effects, both larvae and adult zebrafish may be used to study this at an early stage 
of drug development (16). If cardiotoxic, or other toxic effects are discovered early on this can 
both save pharmaceutical companies for much preclinical research and, most importantly, 
increase patient safety when being discovered prior to clinical trials and entering the market. 
The main goals of the study are to explore the zebrafish as a model for efficacy and toxicity of 
liposomal and free drugs, and as a model for cancer by xenograft transplantation. 
 
In the study, a breast cancer adenocarcinoma cell line (MCF-7) was chosen as the cancer model. 
Even if breast cancer has a relatively high recovery rate (90), many of the therapies, like DOX, 
are toxic and can give severe adverse effects. By using nanoformulations and co-injecting 
statins the goal is to lower the adverse effects, and at the same time target the cancerous tissue. 
 
Firstly, liposomes loaded with SIM, DOX, or both drugs will be produced. These liposomes, 
together with the drugs in free form, will be used to conduct toxicity assays by using intravenous 
injection into the posterior cardinal vein (PCV) of the zebrafish larvae. The effects will be 
studied by observing cardiac changes of the zebrafish larvae prior to injection and at certain 
time points after injection. The co-therapy of SIM will be tested for possible cardioprotective 
effects in anthracycline therapy. The liposomes will also be tested on MCF-7 and H9C2 
cardiomyoblast cells to observe if toxicity of DOX and cardioprotective effects of liposomal 






Additionally, MCF-7 breast cancer cells will be injected into the yolk sac and observed inside 
the zebrafish larvae over time. After establishing a model of how the MCF-7-cells behave inside 
the zebrafish larvae, free and liposomal anti-cancer drugs will be injected, and how these drugs 
distribute inside the zebrafish larvae and around the cancer cells will be observed. Inspection 
by confocal microscopy will be used to determine the effect of the drugs on the cancer cells.  
 
3 Experimental Theory 
3.1 Chromatography 
Chromatography is a separation method used to separate mixtures of various analytes based on 
their physical-chemical properties. The methods normally consist of a mobile and a stationary 
phase. Relative interactions with the mobile and stationary phases determine the separation of 
compounds as defined by the equilibration distribution. The equilibration distribution is given 
by the distribution constant (Kc) which is dependent on the concentration of compound in 





     Equation 1 
 
3.1.1 Size Exclusion Chromatography (SEC) 
SEC separates compounds in a mixture based on their molecular size. The method is based on 
a column material with pores of various sizes. Smaller molecules or particles will enter the 
pores to a larger extent than larger particles and will thereby be retained by the column. This 
results in the largest compounds eluting first, and the smaller compounds eluting later (Figure 
3.1) (92). In the present study SEC is used to separate free from liposomal DOX and SIM and 






Figure 3.1: Size exclusion chromatography. The packing 
material of the column, illustrated as circles, contains pores 
where the largest molecules, illustrated by blue colour, fit only 
into the largest pores or do not fit into the pores at all, and will 
quite freely follow the solvent through the column. The smaller 
molecules, illustrated by yellow colour, will enter the pores 




3.1.2 High Performance Liquid Chromatography (HPLC) 
HPLC is an improved variant of liquid chromatography. Constant flow against high pressure, 
up to 400 times atmospheric pressure, forces the mobile phase through the column containing 
the stationary phase much faster than chromatographic principles based on gravity. The basic 
HPLC system consists of a pump, a sample injector system or an injection loop, a column and 
a detector illustrated in Figure 3.2 (91).  
 
Figure 3.2: High performance liquid 
chromatography (HPLC) system. The HPLC 
system consist of a solvent reservoir containing 
one or more solvents which are pulled into the 
pump generating high pressure. Further along 
is the injection system, where samples for 
analysis enter the system and are separated in 
the column. After separation in the column the 
sample is analyzed by a detector.  
 
In normal phase HPLC the stationary phase is polar, while the mobile phase is non-polar. In 
reversed phase HPLC, the stationary phase is non-polar, and the column is normally packed 
with silica bound to hydrophobic chains. Reverse phase HPLC is suitable for separation of 
molecules dispersed in aqueous solvents and is more frequently used in drug analysis. The 
pump delivers mobile phases into the system at a constant flow. Samples are injected into the 












and the mobile phases are separated in the column. After passing through the column, 
compounds are measured by detectors (91). In this study a UV-Vis diode array detector is used, 
described in section 3.2, to identify and quantify DOX and SIM in liposomes. 
 
3.2 UV-Vis Spectroscopy 
UV-Vis light is light in the ultraviolet (UV) to visible region with wavelengths between 190 to 
800 nm. Different wavelengths of light possess specific amounts of energy. Photons with the 
same energy level as the difference between two energy states of electrons in a molecule can 
be absorbed and bring the electrons to an excited stage (Figure 3.3). The molecular structure 
and functional groups of a compound will determine which wavelength the electrons will 




Figure 3.3: Excitation of electron. Photons with equal energy 
to the difference of two electron energy states can be absorbed 
and the electron enter an exited state. The electron will 
eventually return to the ground state and emit the energy as 
heat and/or radiation (93).   
 
 
There are several different detectors used to measure absorbed light. In this study a photodiode 
array detector is utilized. This detector works by a light source sending polydisperse light onto 
the sample. The wavelengths that are not absorbed by the sample will then be dispersed onto 
the photodiode detector measuring different wavelengths. The light absorbed at specific 
wavelengths can then be calculated (Figure 3.4) (93).  
 
 










Figure 3.4: Photodiode array detector. A photodiode detector used in UV-Vis spectroscopy is 
composed of a light source sending polydisperse light towards the sample where certain 
wavelengths of light are absorbed. The light is then sent to a dispersion device that separates 
the light into different wavelengths which intensities are measured at the diode array detector. 
Figure modified from Analytical Techniques in the Pharmaceutical Sciences, 2016 (93).  
 
As the chemical structure of a compound will determine absorption of light in the UV-Vis 
spectrophotometer and separation in the HPLC column, these methods will together be used to 
create absorption spectrums to identify and quantify SIM and DOX in various samples. 
 
3.3 Infrared Spectroscopy 
Mid Infrared (IR) spectroscopy measures absorption of wavelengths in the IR spectra between 
2500 nm to 25 µm. Absorption in this range is due to molecular vibrations, illustrated in Figure 
3.5. As specific functional groups absorb different wavelengths, the techniques are often used 
to recognize functional groups in compounds (94).  
 
 
Figure 3.5: Molecular vibrations with absorption in the infrared spectra. Molecular 
vibrations, i.e. stretching (A and B) and bending (C and D), absorb infrared radiation, and 
enables the technique to be used to identify functional groups in compounds. 
 
Lipids commonly have distinct groups like their long aliphatic chains and ester carbonyls that 
can be recognized by IR absorption. This makes it possible to quantify lipid content in a sample 
by first creating a standard curve with known concentrations. In this study a Direct Detect® 
spectrophotometer was used to rapidly quantify lipid content in liposomes by adding a few 
microliters of liposome suspension onto the Direct Detect® assay free cards. This method gives 
an easy and fast determination of lipid content (95). 
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3.4 Dynamic Light Scattering 
Dynamic light scattering (DLS) is a technique used to measure size and polydispersity of 
colloidal particles in a medium (96). The method utilizes the Brownian motion of particles, 
which are the random and irregular movements of particles in a medium caused by the particles 
collisions with the molecules in the medium, for instance water molecules (97). Light sent at 
the particles at a set position will scatter the light at the detector where it is measured. Due to 
Brownian motions, the light scattering will change over time (96). As Brownian motion of 
particles are related to their size, the detected signal can then be converted into particle size and 
size distribution (97, 98). The technique requires the particles to be spherical and the refractive 
index of the particles and medium as well as the viscosity of the dispersion medium to be known 
in order to achieve the correct correlation between the detected signal and particle size (99). 
 
3.5 Confocal Microscopy 
A confocal microscope is based on the same principles as a conventional microscope but with 
pinholes which should reject out-of-focus planes. This gives clearer images without interfering 
signals from other z-planes above or below focus illustrated in Figure 3.6 (100).  
 
Figure 3.6: Principles of confocal microscopy. 
The simplified image of a confocal microscope 
illustrates how the confocal pinholes reject the 
out-of-focus planes in z-direction in a three-
dimensional sample. This result in clear images 
without interfering signals from other z-planes. 
Figure obtained from (101). 
 
 
Spinning disc confocal microscopy (SDCM) contains a rotating pinhole disc splitting the laser 
into multiple laser beams. One of the advantages of SDCM is that this method enables faster 
imaging, as the image is acquired using multiple beams and pinholes. At the same time the 
method gives lower phototoxicity when imaging live specimens. The specimens are both 
exposed to the laser for a shorter amount of time, and the laser beam is weakened after being 
split by the pinhole disc (102). When observing objects in a confocal microscope, fluorescence 





atoms go back to their ground state they can emit light at different wavelengths which are 
possible to observe in the microscope (103, 104).  
 
3.6 Cell Lines 
Cell lines are clonal population of immortalized cells often used in research as a replacement 
of primary cells. These cells have several advantages including low cost and an unlimited 
number of cells available providing high reproducibility of studies (105). Continuous cell lines 
are produced by primary cells, which either spontaneously or induced, undergo transformation 
and after this obtain the feature of dividing indefinitely (106). 
 
In this study two cell lines will be used. The first is MCF-7, an adenocarcinoma breast cancer 
cell line derived from a 69-year old woman (107). This cell line will be used to test the effect 
of liposomes loaded with DOX and SIM and will also be transplanted into zebrafish larvae to 
mimic and observe breast cancer in zebrafish. The second cell line used in the study is H9C2, 
cardiomyoblast cells derived from the heart of rat embryo (108).  
 
3.7 Cell Proliferation and Viability Assays 
Cell proliferation and viability assays are used to determine viability and proliferation of cells. 
One way to measure cell viability and proliferation is by using the compound 4-[3-(4-
Iodophenyl)-2-(4-nitro-phenyl)-2H-5-tetrazolio]-1,3-benzene sulfonate (WST-1). The 
mitochondrial succinate-tetrazolium-reductase system is able to open the tetrazole ring of WST-
1, creating a dark red formazan compound (Figure 3.7). More viable, or a higher number of 
cells has a higher total enzyme activity, and more WST-1 will be reduced. The amount of the 








Figure 3.7: WST-1 formation into formazan. The light red colored WST-1 molecule is inside 
the mitochondrial succinate-tetrazolium-reductase system converted into the dark red 
formazan compound by reducing and cleaving the tetrazole ring of the molecule. An increased 
number of viable cells will be able to reduce more WST-1, creating a darker red color which 
can be measured. Figure adapted from Merck Life Sciences (109).  
 
 
3.8 Cell Staining 
For red fluorescent cells the cell stain 1,1’-Dioctadecyl-3,3,3’,3’-Tetramethylindocarbocyanine 
Perchlorate (DiI) was used. The lipophilic dye stains the cell membrane and diffuses throughout 
the entire membrane to stain the whole cell. DiI does not exchange between neighboring cells, 
but will be transferred to daughter cells during mitosis, and can be used to trace cell migration 
and proliferation after transplantation (110).  
 
CellTracker™ Green CMFDA (5-chloromethylfluorescein diacetate) hereby referred to as 
CTG, is a green fluorescent cell stain used in the study. The stain diffuses freely into cells where 
intracellular esterases transforms the stain into a lipophilic, fluorescent product which is unable 
to exit the cell (Figure 3.8). The stain should be visible for no less than 72 hours, and does not 























Figure 3.8: Removal of acetate groups on CellTracker™ Green CMFDA (CTG). CTG is a 
non-fluorescent compound before it enters cells. Intracellular esterases cleave the ester groups 
on the molecule and thereby creates a fluorescent, lipophilic product unable to exit the cells 
(right) (113). 
 
4 Materials and Methods 
4.1 Materials 
Hydrogenated Egg Phosphatidylcholine (HEPC) was from Lipoid GmbH (Ludwigshafen, 
Germany). 1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine-N-[Methoxy (Polyethylene 
glycol)-2000] (Ammonium salt) (PEG-PE) was from Avanti Polar Lipids (Alabaster, USA). 
ATTO-488 DPPE was from Atto-Tec (Siegen, Germany). Acetonitrile (ACN) was from Merck 
Millipore (Darmstadt, Germany). Doxorubicin (DOX) was from Accord Healthcare (London, 
GB). SephadexTM G-50 was from GF Healthcare (Chicago, USA). Microcapillaries were from 
Clark Electromedical Instruments (Holliston, USA). Hoechst33342 DNA stain, CellTracker 
Green CMFDA and 1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindo-carbocyanine Perchlorate 
('DiI'; DiIC18(3)) (DiI) was from ThermoFisher Scientific (CA, USA). WST-1 cell 
proliferation agent was from Roche Diagnostics GmbH (Mannheim, Germany). Milli-Q water 
(MQ) was produced at the laboratory by a Merck Millipore Q-POD (Darmstadt, Germany). All 
remaining materials were from Sigma-Aldrich (St. Louis, Missouri, USA) and were of analysis 
grade.   
 
Zebrafish embryos and embryo water were provided from the zebrafish facility at the 




















4.2  Liposome Production and Quantification 
4.2.1 Production Procedure 
4.2.1.1 General procedure 
Lipids dissolved in chloroform were added to a round bottom flask. The flask was fit on a rotary 
evaporator in a room tempered water bath and the chloroform evaporated at mild vacuum at 
225 mbar for 30 minutes, 175 mbar until dry, followed by full pump capacity for 30 minutes to 
remove any residual chloroform. The resulting film was rehydrated by adding either 225 mM 
ammonium sulphate buffer (ASB) or phosphate buffered saline (PBS) preheated to 70 °C and 
alternating vortexing and heating the flask in a 70 °C water bath until there was no trace of the 
film left in the flask. The suspension was extruded eleven times each through 0.8, 0.4, 0.2, and 
0.1 µm filters, the latter size repeated twice, using an Avanti Polar Lipids Mini Extruder 
(Alabaster, US) preheated to 70 °C and fitted with Whatman® Nuclepore™ Track-Etched 
membrane filters (Maidstone, GB) and filter supports from Avanti Polar Lipids Inc. 
 
4.2.1.2 Production of ATTO-488 DPPE Fluorescent Liposomes 
For production of fluorescent liposomes, the lipid film was made using 2.40 mg HEPC, 0.62 
mg cholesterol and 0.70 mg PEG-PE, and 12 µg ATTO-488 DPPE, a green fluorescent 
phospholipid, to the flask. The film was rehydrated using two mL PBS pH 7.4.  
 
4.2.1.3 Production of DOX Filled Liposomes 
The lipid film was made using exactly 4.80 mg HEPC, 1.23 mg cholesterol and 1.39 mg PEG-
PE and rehydrated by adding one mL ASB (pH 6.0). Following extrusion, the suspension was 
gel filtered through a SEC column (1 cm diameter, 20 cm length) packed with sepharose beads 
(Sephadex™ G-50) and equilibrated with PBS pH 8. The liposomes were collected, and the 
lipid concentration measured as defined in section 4.2.2.1. Two mg/mL DOX dissolved in 
DMSO was added up to 20% w/w of the lipid concentration and incubated for one hour at 70°C 
followed by refrigerator overnight. 
 
4.2.1.4 Production of SIM liposomes 
A lipid film was made from exactly 54.5 mg HEPC, 0.32 mg cholesterol and 0.35 mg PEG-PE 
and 3.25 mg SIM in the flask. The film was rehydrated in one mL ASB (pH 6.0). After 
extrusion, the suspension was centrifuged at 10 000 relative centrifugal force (RCF) at 4° C for 





column as described in section 4.2.1.3. If the liposomes were to be loaded with DOX in addition 
to SIM, DOX was added at desired concentrations up to 20% of the lipid concentration, 
incubated for one hour at 70° C, followed by refrigerator overnight.  
 
4.2.2 Quantitative Analysis of Liposomes 
4.2.2.1 Liposome characterization  
The lipid concentration of the liposome suspension was measured by using a Merck Millipore 
Direct Detect® infrared spectrometer (Darmstadt, Germany). Two µL of the liposome 
suspension was added to the sample cards using PBS as blank. Using a previously made 
standard curve the w/v concentration was calculated using Equation 2 where 𝑦 is the 
absorbance, and 𝑥 is the lipid concentration (114).   
 
𝑦 = 0,0147𝑥     Equation 2 
 
The liposome size was found by using a Malvern Panalytical Zetasizer nano ZS (Malvern, GB) 
DLS device. Twenty µL of the liposome samples diluted in one mL PBS pH 8 were added to 
disposable cuvettes. Refractive indexes of the sample and dispersion media were set to 1.450 
and 1.330, respectively and absorption of the sample was set to 0.001. Temperature was set to 
25 °C. Each test consisted of twelve ten-second scans, which was repeated three times for each 
sample. Automatic mode was used to find optimal laser position, measurement duration and 
number of scans. 
 
4.2.2.2 Quantification of DOX concentration in liposomes 
HPLC was used for quantifying the concentrations of DOX and SIM in the liposomes. The 
HPLC system used was a HITACHI Chromaster 5160 pump, 5260 autosampler and 5430 diode 
array detector (Tokyo, Japan) and a Merck L-7614 degasser (Darmstadt, Germany). 
 
For DOX quantification, a volume of 50 µL DOX-liposome suspension were filtered through 
the SEC column and collected in 20 fractions of 719 µL each. From each fraction, 50 µL were 
added first 50 µL ACN followed by 50 µL MQ, and from this, ten µL samples was injected 
onto a reversed phase column (Kromasil C18, 100-5 4.6x150 mm fitted with a 4.6x10 mm 
guard column with the same solid phase). The mobile phases were 0.05% TFA in MQ (mobile 





The duration for each sample was 8 minutes with a flow rate at 1.4 mL/min. A standard curve 
was made by linear regression of seven standard solutions of DOX in 3:7 ACN:MQ ranging 
from 0.005 to 0.12 mg/mL DOX.  
 
Table 4.1: HPLC gradient for doxorubicin (DOX) quantification in liposomes. Mobile phase 
A is 0.05% trifluoroacetic acid in Milli-Q water and B is 0.05% trifluoroacetic acid in 
acetonitrile for DOX quantification on a C18 column. 
Time (minutes) 0 1 3 4 5 6 8 
A (%) 70 70 30 0 0 70 70 
B (%) 30 30 70 100 100 30 30 
 
The elution of DOX in liposomes was compared to elution of ATTO-488 DPPE fluorescent 
liposomes through the same SEC column used for the DOX liposomes equilibrated with PBS 
pH 7. The liposomes were collected in 19 fractions of 360 µL each. The fluorescence was 
measured using a Wallac EnVision™ 2103 Multilabel reader (PerkinElmer, Massachusetts, 
U.S.) fitted with excitation and emission filters of FITC 485 and FITC 527 nm, respectively. 
 
For encapsulation efficiency of DOX in the SIM-DOX liposomes, 40 µL 0.4 mg/mL DOX in 
SIM-DOX liposomes and free DOX was added in two separate runs to the SEC column. The 
liposomal DOX was collected into 45 fractions of 381 µL each. Free DOX was collected into 
20 fractions of 952 µL each. From each of these samples, 100 µL was added to a black 96-well 
plate and fluorescence measured using the Wallac EnVision™ 2103 Multilabel reader with 
excitation and emission filters at FITC 485 nm and rhodamine 590 nm, respectively, to identify 
the DOX containing fractions. This was then used to determine the elution volume of free DOX 
and DOX in SIM-DOX liposomes.  
 
4.2.2.3 Quantifying SIM concentration in liposomes 
Three different HPLC methods were tried to quantify SIM content. The first method was based 
on a previous study (114), and utilized the same C18 column described in section 4.2.2.2 with 
mobile phases A and B, being 0.05% TFA in MQ and 0.05% TFA in ACN, respectively with 
the gradient described in Table 4.2 A. The method had a flow rate of 1.4 mL/min, 13 minutes 
sample duration and 10 µL sample injections. The second method used an Agilent poroshell 





The mobile phases were MQ, ACN and methanol with gradient as described in Table 4.2 B, a 
flow rate of 0.350 mL/min. The last test was done using the same phenyl-hexyl column and 
mobile phases as above, but with a flow rate of 0.400 mL/min and a gradient as described in 
Table 4.2 C.  
 
Table 4.2: HPLC mobile phase gradients for simvastatin (SIM) quantification. 1: Mobile 
phase gradient for SIM quantification test one using a C18 column. The test was conducted 
using mobile phases A (Milli-Q water (MQ) with 0.05% trifluoroacetic acid) and B (acetonitrile 
(ACN) with 0.05% trifluoroacetic acid). 2: Mobile phase gradient used for the first method with 
a phenyl-hexyl column with the mobile phases C, D and E being MQ, ACN and methanol, 
respectively. 3: The mobile phase gradients for the second test using a phenyl-hexyl column to 
quantify SIM with mobile phases C, D and E.  
1: 
Time (min) 0 1 7 8 10 13 
A (%) 70 70 0 0 70 70 





Time (min) 0 1 17 20 21 23 31 
C (%) 20 20 0 0 0 20 20 
D (%) 0 0 40 100 100 0 0 
E (%) 80 80 60 0 0 80 80 
 
To analyze the content of SIM in the liposomes, 50 µL of the liposome suspension was 
evaporated at room temperature using an Eppendorf Concentrator Plus vacuumed centrifuge 
(Hamburg, Germany) until dry. The remaining pellet was rehydrated by adding 112 µL 
Time (min) 0 3 8 24 26 30 
C (%) 20 20 0 0 20 20 
D (%) 0 0 0 100 0 0 





methanol, followed by 28 µL MQ and mixed with the pipette to dissolve the pellet before HPLC 
analyses.  
 
4.3 Maintenance of Cell Lines  
The cells used in the study were H9C2 (ATCC® CRL-1446™) and MCF-7 (ATCC® HTC-
22™), described in Section 3.6. The MCF-7 and H9C2 cells were cultured in Minimum 
Essentials Medium Eagle (MEM) and Dulbecco’s Modified Eagle Medium (DMEM), 
respectively. Both media were added 10% v/v fetal bovine serum, 100 IU/mL penicillin and 
100 µg/mL streptomycin, 2 mM L-glutamate and the MEM medium was also added 1% non-
essential amino acids. All cell culturing medium, serum and additives were from Sigma-Aldrich 
(St. Louis, MO, USA). Both lines were cultured in 75 cm2 tissue flasks and split 1:4 after 
reaching 70-85% confluence (115, 116). To detach the cells, the medium was removed, and the 
cells washed twice with sterile PBS. The cells were added 1.5 mL trypsin, incubating for 5-15 
minutes at 37 °C until cells were observed to detach from the flask. After trypsinization, ten 
mL medium was added to the flask and the cells further detached by gentle pipetting. The cell 
suspension was centrifuged at 150 RCF for five minutes, the supernatant was removed, and the 
cells resuspended in one mL medium.  
 
For further culturing, new flasks were filled with 30 mL fresh medium and added ¼ of the cell 
suspension harvested from one flask. 
 
4.4 Labeling Cells with Fluorescent Cell Stains 
4.4.1 Labeling Adhered MCF-7 Cells with DiI Stain 
A one mg/mL stock solution of DiI was prepared in ethanol (110). MCF-7 cells were cultured 
to 70-85% confluence in 25 cm2 tissue flasks for staining. The cell medium in the flask was 
removed and the cells washed once with sterile PBS. DiI in MEM medium at a concentration 
of 0.005 mg/mL was added to the cells and incubated at 37 °C for one to two hours (110). The 
medium was removed, and the cells washed twice with sterile PBS. The cells were next 
trypsinated as described in section 4.3 and counted using a Bürker counting chamber and the 






4.4.2 Labeling Suspended MCF-7 Cells with CTG Stain 
CTG was dissolved to ten mM solution in DMSO, and further diluted to ten µM in serum free 
MEM medium (111). The cells were detached as described in section 4.3, washed twice with 
PBS, and mixed with one mL medium. The suspension was centrifuged at 150 RCF for five 
minutes, the supernatant removed and two mL of the ten µM staining solution added, mixed 
with the cells and incubated for 30 minutes at 37 °C (111). The cells were counted, the medium 
removed, and the cells washed and added fresh medium to obtain a cell concentration of two 
million cells per mL.  
 
4.4.3 Co-Labeling of Adherent MCF-7 Cells with CTG and DiI Stain 
CTG was dissolved to 10 mM solution in DMSO, and further diluted to 10 µM in serum free 
MEM medium. The medium was added DiI stock solution from section 4.4.1 to a concentration 
of 0.005 mg/mL and mixed. The cell medium was removed, and cells washed twice with sterile 
PBS before being added ten mL of the CTG-DiI medium solution. The cells were incubated for 
one hour at 37 °C. The medium was removed, and the cells trypsinated as described in section 
4.3. The cells were counted, and volume adjusted to a cell count of five million cells per mL.  
 
4.5 Cell Viability Assays 
Ten thousand MCF-7 or H9C2 cells were added per well to 96-well cell culture plates and 
incubated for 24 hours. The medium was then removed and 100 µL of fresh medium containing 
drugs or liposomes was added. Table 4.3 show the experimental conditions. After 24 or 48 
hours each well was added 10 µL WST-1 cell proliferation agent and incubated for two hours. 
Following this, a Wallac EnVision™ 2103 Multilabel reader fitted with 450 nm filter, with the 
reference filter at 620 nm was used to measure absorbance of the wells. After measuring 
metabolic activity, 100 µL 4% buffered formaldehyde solution with Hoechst 33342 (0.01 
mg/mL) was added to each well. The plates were stored at 4 °C in the dark until observation in 
a Nikon Diaphot 300 inverted microscope fitted with a Nikon DS-Fi3 microscope camera and 
DS-L4 camera control unit (Tokyo, Japan). Three images were obtained from each condition 










Table 4.3: Cell viability assay conditions. Free doxorubicin (DOX), simvastatin (SIM) and 
SIM-DOX liposomes were diluted in cell medium adequate for the respective cells. From the 
solutions, 100 µL were added to MCF-7 or H9C2 cells in 96-well plates. All conditions were 
tested in triplets. 
Conditions Concentrations 
Control A Medium 
Control B Medium and 10% PBS  
SIM-DOX liposomes 15 µM DOX + 4.67 µM SIM  
5 µM DOX + 1.51 µM SIM 
2.5 µM DOX + 0.71 µM SIM 
0.5 µM DOX + 0.15 µM SIM 
Free DOX 15 µM DOX 
5 µM DOX 
2.5 µM DOX 
0.5 µM DOX 
Free SIM  4.67 µM SIM  
1.51 µM SIM 
0.71 µM SIM 
0.15 µM SIM 
Free SIM and DOX  15 µM DOX + 4.67 µM SIM  
5 µM DOX + 1.51 µM SIM 
2.5 µM DOX + 0.71 µM SIM 
0.5 µM DOX + 0.15 µM SIM 
 
4.6  Zebrafish Handling and Experimental Conditions 
4.6.1 Zebrafish Embryo and Larvae Care 
Zebrafish embryos were obtained from the zebrafish facility at the Department of Bioscience, 
University of Bergen. The zebrafish used were of the strain Casper. A maximum of ten adult 
zebrafish (approximately equal amount of male and female fish) were put in breeding tanks 





collected the next morning and kept in an incubator at 28.5°C in petri dishes containing embryo 
water blue (117, 118). The petri dishes were cleaned for debris and dead embryos daily. 
 
As zebrafish embryos hatch between 48 to 72 hpf, they were in some cases dechorionated 
between 24 and 48 hpf to be used before hatching. This was done using two syringe needles 
and carefully gripping separate ends of the chorion. The chorion was then pulled apart by the 
needles causing the zebrafish larvae to escape into the embryo water (119).  
 
4.6.2 General Methods for Injections 
Micropipettes were pulled from microcapillaries using a P-1000 Micropipette puller by Sutter 
Instruments (Novato, CA, US). The capillaries were of thin walled borosilicate glass with outer 
diameter of 1.0 mm, inner diameter of 0.78 mm and length of 10 cm (Clark description 
GC100TF-10) and pulled with the settings given in Table 4.4. The micropipettes were 
retrograde filled with injection solution, then fitted on a Femtojet 4x by Eppendorf (Hamburg, 
Germany) and the micropipette tip was emerged in a thin layer of groundnut oil in a petri dish 
on top of a one mm grid with 0.1 mm intervals. The tip was cut using a scalpel after the 
micropipette was fully emerged in the oil. The size of the drop was measured, with an 
acceptable diameter being between 0.1- and 0.2 mm. Equation 3, the equation for the volume 
of a sphere, was used to calculate injection volume. In Equation 3, 𝑉 is volume and 𝑟 is the 
radius of the drop. To adjust injection volume, injection time (0.1-0.4 seconds) and injection 




𝜋𝑟#      Equation 3 
 
Table 4.4: Micropipette production settings. Settings on the Sutter Instruments P-1000 
Micropipette puller for production of micropipettes from borosilicate glass capillaries with 
inner diameter 0.78 mm, outer diameter 1.0 mm and length 10 cm for microinjections into 
zebrafish posterior cardinal vein and yolk sac.  
Heat Pull Velocity Delay Pressure 
482 80 70 150 200 
 
Tricaine (Ethyl 3-aminobenzoate methanesulfonate) was used for sedation of the zebrafish larva 





MQ and 1.05 mL Tris-HCl (pH 9). The stock solution was diluted further in Embryo Water 
Blue (E3) to a 0.2 mg/mL solution (120). The larvae were placed into the solution at least 10 
minutes prior to visualization or injection.  
 
Injections were performed intravenously into the posterior cardinal vein (PCV) or into the yolk 
sac (Figure 4.1). Cancer cells were injected intravenously or the yolk sac, and drugs were 
injected into the PCV or dissolved in embryo water. Cells for xenograft transplantation were 
stained as described in section 4.4 and kept on ice until injection.  
 
 
Figure 4.1: Intravenous and yolk sac injections in zebrafish larva. A: A zebrafish larva with 
the micropipette placed in position for injection in the posterior cardinal vein (PCV). PCV (blue 
arrow) can easily be distinguished from the dorsal aorta (red arrow) in the microscope by the 
direction of blood flow. Orange arrows point to the micropipette and the heart of the larva. B: 
The micropipette inserted into the yolk sac with arrow pointing towards the micropipette. C: 
The yolk sac directly after injection of the cell suspension with the blue circle surrounding the 
injected volume of cell suspension. Images obtained using a Leica M205 stereo microscope. 
Scale bar: A: 250 µm, B: 200 µm. 
When observing HR and other physiologic effects of drugs on zebrafish, a Leica M205 stereo 
microscope and a Leica DFC3000 G camera combined with the Leica Application Suite X 
software was used to obtain movies and still images. The HR was found by filming each larva 
for 10 seconds and calculating beats per minute (bpm). See Appendix, Supplementary Figure 1 














Injected cancer cells and blood distribution of liposomes were visualized using an Andor 
Dragonfly 505 confocal with cameras iXon 888 Life EMCCD and Zyla 4.2 PLUS sCMOS 
(Andor Technology Ltd, Belfast, GB) fitted with a Nikon inverted Ti-E microscope (Tokyo, 
Japan). The zebrafish larvae were placed individually in 96-well plates containing embryo 
water and sedated in tricaine solution at observations. The iXon camera was used to image the 
cancer cells or liposomes inside the zebrafish using 10x and 20x dry objectives and green (laser 
line 405 nm) and red (laser line 561 nm) fluorescent filters. Imaris (Oxford Instruments) was 
used to observe and analyze confocal images and FIJI software was used to analyze area and 
number of fluorescent events in cell injected zebrafish larvae by using the Analyze Particle 
function in images with maximum intensity from the z-stack.  
 
4.7 Statistics 
Graphs were created and Students t-test performed in Microsoft Excel for Mac version 16.37 
(Microsoft). One-way analysis of variance (ANOVA) and least significant difference (LSD) 
post hoc tests were performed in SPSS Statistics version 26 for Mac (IBM Corporation). 




5.1 Liposome Characterization 
5.1.1 Drug Content in Liposomes 
From HPLC, Figure 5.1 show the chromatogram for the 0.12 mg/mL DOX standard solution 
and illustrates DOX eluting as one single peak with maximum absorbance at 2.31 minutes 
retention time, where there were low levels of or interferences from the gradient. The inset 
shows the standard curve obtained with a linear relationship between DOX concentration and 
peak area giving the equation further used to calculate encapsulation of DOX. A small 
disturbance in the baseline is observed immediate left of the DOX peak, seen to be the same 













Figure 5.1: HPLC chromatogram and standard curve of doxorubicin (DOX). HPLC 
chromatogram for a 0.12 mg/mL standard solution of DOX obtained with a C18 column and 
mobile phases Milli-Q water and acetonitrile, both added 0.05% trifluoroacetic acid. Injection 
and DOX detection peaks are marked with arrows. The inset shows the standard curve obtained 
with DOX standard solutions with concentrations from 0.05 to 0.12 mg/mL DOX. See methods 
section for details on instrumentation and experimental set-up.  
 
 
The first SIM quantification test on HPLC was performed using the same C18 column used for 
the DOX analysis and the mobile phase gradient from Table 4.2 A and resulted in the 
chromatogram illustrated in Figure 5.2. The SIM peak eluted at 9.93 minutes, at the same time 
as the wash and equilibration of the column with ACN, which causes the baseline to be noisy, 















































Figure 5.2: HPLC chromatogram for analysis of simvastatin (SIM) on a C18 column. The 
chromatogram for SIM injected onto a C18 column and mobile phase gradient for Milli-Q 
water and acetonitrile (ACN), both with 0.05% trifluoroacetic acid (TFA). Chromatogram of 
SIM illustrated as a black line, and mobile phase fractions as orange and grey lines for Milli-
Q water and ACN, respectively. 
 
 
Next, a phenyl-hexyl column was used with the mobile phases from Table 4.2 B in Methods 
section. However, this also gave a chromatogram with a noisy baseline, where it was hard to 
distinguish the SIM peak (chromatogram not illustrated). The gradient in Table 4.2 C, using the 
same phenyl-hexyl column, but methanol as the main eluting mobile phase produced the 
chromatogram displayed in Figure 5.3. With this method, the baseline had low noise levels, and 
SIM eluted as a narrow peak with a retention time of 14.6 minutes (Figure 5.3 A). The standard 
solutions provided a linear relationship between peak area and SIM concentrations giving the 


























































Figure 5.3: HPLC chromatogram and standard curve for simvastatin (SIM). A: 
Chromatogram of a five µL injection of 0.16 mg/mL SIM standard solution analyzed on a 
phenyl-hexyl column with mobile phases acetonitrile (ACN), Milli-Q water and methanol 
(MeOH). The chromatogram is illustrated as a black line, while mobile phase gradient fractions 
for ACN, Milli-Q and MeOH are showed as grey, orange and blue lines, respectively. The 
sample injection and SIM signal are marked with arrows. B: The standard curve obtained by 
analyses of SIM standard solutions ranging from 0.0016-0.16 mg/mL. See the methods section 
for instrumentation and experimental setup. 
 
To separate encapsulated from free DOX in liposomes, they were gel filtered on a SEC column 
and compared to the elution of a batch ATTO-488 DPPE liposomes or free DOX. The drug in 
DOX liposomes and in SIM-DOX liposomes were found to have an elution volume between 
three to eight mL and four to eight mL, respectively. The peaks overlapped with the elution of 
the ATTO-488 DPPE liposomes, confirming that the DOX in the peaks was encapsulated 
(Figure 5.4). Only trace amounts of DOX was detected after the main peak. Calculations of area 



















































































3.60 and 7.19 mL in the DOX liposomes (Figure 5.4 A). For the SIM-DOX liposomes as well, 
no peak was observed after the main liposomal peak (Figure 5.4 B). Free DOX began to elute 
after approximately 9.5 mL with a broad peak that was still not fully eluted after 19 mL at the 
last fraction and did not overlap with the elution of the liposomes (Figure 5.4 B). 
 
 Figure 5.4: Size exclusion chromatography (SEC) of drug-loaded liposomes. A: Doxorubicin 
(DOX) liposomes and ATTO-488 DPPE labeled liposomes were separately added to a SEC 
column packed with Sephadex beads, and fractions collected. The concentration of DOX in the 
fractions were measured using HPLC, and the ATTO-488 DPPE liposome fractions measured 
with a Wallac EnVision™ plate reader (excitation: 485 nm, emission: 527 nm) to quantify 
fluorescent marker. B: Simvastatin-DOX liposomes and free DOX was separately added to a 
SEC column and fractions collected. The fractions were analyzed for DOX content by 
measuring fluorescence in the Wallac EnVision™ plate reader (excitation 485 nm, emission: 
























































































5.1.2 Size and Lipid Concentration of Liposomes  
The empty liposomes were found to be 130 nm in diameter with a polydispersity index of 0.021 
using DLS. The lipid concentration in the liposomes was calculated to be between 2.5 and 3.0 
mg/mL. The SIM liposomes had a lipid concentration between 5.3 and 7.4 mg/mL, a diameter 
of 128 nm and a polydispersity index of 0.056. The liposome size was not measured after 
addition of DOX, but Knudsen (114) and Myhren et al. (121) found that encapsulation of 
anthracyclines did not alter liposome size. 
 
Table 5.1: Size, lipid concentration and drug loading of liposomes in the study. 








Empty 130 2.5-3.0 - - 
DOX -* 1.9-2.25 0.45-0.50 - 
SIM 128 5.3-7.4 - 0.3 
SIM-DOX -* 2.24 0.45 0.09 
*Size was not measured after addition of DOX in liposomes. 
 
5.2 Cytotoxic Activity of Free and Liposomal Drugs 
Two methods were used to measure cell viability, but because of poor correlation between the 
two methods, counting the fractions of viable cells in a microscope was chosen as the most 
reliable method. The viability calculated from the WST-1 proliferation assay is illustrated in 
Supplementary Figure 3. In a microscope, cells with normal morphology and apoptotic or 
necrotic cells were counted to estimate cell viability following incubation with drugs. Necrotic 
or apoptotic nuclei were observed as pyknotic, condensed and sometimes fragmented when 
observed in the microscope, while normal nuclei were seen as larger and less intensely stained 
as observed in Figure 5.6 A and B (122). 
 
In Figure 5.5, MCF-7 cells from the 24-hour incubation assay are displayed. Cells treated with 
4.67 µM free SIM (Figure 5.5 D) appears similar to the control (Figure 5.5 A), as does SIM-
DOX liposomes, however, the latter has lower contrast in the image (Figure 5.5 E), indicating 
less Hoechst in the nuclei. In Figure 5.5 B the cells are detached from the well, many cells are 
smaller relative to untreated cells and have clustered together in the medium. This is also the 





the well with weaker fluorescence. See Figure 5.6 A to observe how normal MCF-7 cells would 
look in bright field.  
 
 
Figure 5.5: Morphology of MCF-7 cells after 24 hours of exposure to drug formulations. 
MCF-7 cells were incubated for 24 hours with doxorubicin (DOX), simvastatin (SIM) or a 
combination, free and liposomal, before being fixed in 2% formaldehyde solution with 
Hoechst33342. A: Control cells incubated with cell medium. B: Cells incubated with 15 µM 
free DOX. C: Cells incubated with 15 µM free DOX and 4.67 µM free SIM. The arrows point 
to cells with normal morphology in the images. D: Cells incubated with 4.67 µM free SIM. E: 
Cells incubated with DOX-SIM liposomes. Images were obtained in a Nikon Diaphot 300 
inverted microscope at 20x magnification with a rhodamine filter (red), a DAPI filter (blue) or 
in bright field (grey). Scale bar: 50 µm. 
 
Figure 5.6 illustrates MCF-7 cells incubated for 48 hours with the highest drug concentrations. 
Free SIM did not appear to affect viability and nuclear morphology resembled that of the control 
wells (Figure 5.6 D and A). All cells treated with 15 µM free DOX were apoptotic or necrotic, 
A) Control B) Free DOX C) Free DOX and SIM





and no longer adhered to the surface. Co-treatment with SIM did not affect viability compared 
to treatment with DOX alone (Figure 5.6 B and C). The image from the cells treated with SIM-
DOX liposomes for 48 hours showed several apoptotic cells (Figure 5.6 E).  
 
 
Figure 5.6: Morphology of MCF-7 cells after 48 hours exposure to drug formulations. MCF-
7 cells were incubated for 48 hours with doxorubicin (DOX), simvastatin (SIM) or both, free 
and liposomal before being fixed in 2% formaldehyde solution with Hoechst33342. A: Control 
cells. B: Cells incubated with 15 µM free DOX. C: Cells incubated with 15 µM free DOX and 
4.67 µM free SIM. D: Cells incubated with 4.67 µM free SIM. E: Cells incubated with DOX-
SIM liposomes. Images were obtained in a Nikon Diaphot 300 inverted microscope at 20x 
magnification with a rhodamine filter (red), a DAPI filter (blue) or in bright field (grey). Scale 
bar: 50 µm. 
 
The H9C2 cells were incubated for 24 hours with the same drug combinations are displayed in 
Figure 5.7. In both Figure 5.7 B and C there are cells still attached to the well. However, the 
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concentrates in the nuclei, and the cells were therefore considered as necrotic. The cells still 
attached in Figure 5.7 C, are observed to have higher fluorescent signal in the nucleus and are 
therefore considered as viable. The H9C2 cell wells treated with DOX-SIM liposomes also 
gave a lower contrast using the DAPI filter, as observed for MCF-7, but no decreased viability 
was observed (Figure 5.7 E). 
 
 
Figure 5.7: Morphology of H9C2 cells incubated for 24 hours with drugs formulations. 
H9C2 cells were incubated for 24 hours with doxorubicin (DOX), simvastatin (SIM) or both, 
free and liposomal before being fixed in 2% formaldehyde solution with Hoechst33342. A: 
Control cells incubated with cell medium. B: Cells incubated with 15 µM free DOX with arrows 
pointing to adherent cells in the well. C: Cells incubated with 15 µM DOX and 4.67 µM SIM 
and arrows pointing to adherent cells in the image. D: Cells incubated with 4.67 µM SIM. E: 
Cells incubated with DOX-SIM liposomes. Images were obtained in a Nikon Diaphot 300 
inverted microscope at 20x magnification with a rhodamine filter (red), a DAPI filter (blue) or 
in bright field (grey). Scale bar: 50 µm. 
 
A B
50 µm 50 µm
D) Free SIM E) DOX-SIM liposomes





Neither control B, SIM, nor SIM-DOX liposomes in any concentration altered MCF-7 cell 
viability compared to control after 24 hours (Figure 5.8 A). There was a dose-dependent 
increase in cell death in cells treated with DOX, both alone and in co-treatment with SIM 
(Figure 5.8 A). There were, however, differences between the cells depending on SIM co-
therapy (Table 5.2 A). For the cells receiving 2.5 µM free DOX, co-therapy with SIM gave a 
significant decrease in viability (P < 0.05) compared to those receiving DOX alone (Figure 5.8 
A and Table 5.2 A). The remaining concentrations of DOX gave no change in viability between 
those receiving free DOX alone and those receiving free DOX and SIM (Figure 5.8 A and Table 
5.2 A). 
 
MCF-7 cells treated with drugs for 48 hours had a significant decrease in viability when treated 
with the highest concentration of SIM-DOX liposomes with P < 0.001 compared to control A. 
The viability of these cells was still significantly higher than cells treated with equal 
concentrations of free DOX (P < 0.001, Figure 5.8 B and Table 5.2 B). There was also a 
decrease in viable cells treated with 2.5 µM DOX and 0.71 µM SIM compared to those treated 
with 2.5 µM free DOX alone (P < 0.005) while no significant change in the higher 
concentrations (Figure 5.8 B and Table 5.2 B). After 48 hours of incubation, SIM alone did still 
not cause any change in viability relative to control in MCF-7. Neither did 0.5 µM free DOX 
nor the SIM-DOX liposomes in concentrations 5 µM or lower (Figure 5.8 B). 
 
For H9C2 cells, co-treatment with DOX and SIM gave significant less cell death compared to 
treatment with DOX alone in the 15 µM DOX concentrations (Figure 5.8 C and Table 5.2 C). 
There was, however, a significant decrease in viability for 0.5 and 2.5 µM free DOX when in 
co-treatment with free SIM, with P < 0.005 and < 0.001, respectively (Figure 5.8 C and Table 
5.2 C). There was not observed any change in viability for cells treated with Control B, SIM-
DOX liposomes nor free SIM in any concentration. 
 
In general, H9C2 cells appeared to tolerate higher concentrations of DOX (5 and 15 µM) 
relative to MCF-7 over 24 hours, both with and without co-treatment of SIM. SIM treatment 
alone did not show toxicity in any concentration for whether MCF-7 or H9C2. The SIM-DOX 
liposomes did not show cytotoxicity in either cell line after 24 hours of incubation, but some 





(Figure 5.8 and Table 5.2). For all of the cell assays, there was a significant decrease in viability 
for the 2.5 µM free DOX concentration when in co-treatment with SIM (Table 5.2). 
 
Figure 5.8: Cytotoxic response in MCF-7 and H9C2 cells treated with doxorubicin (DOX) 
and simvastatin (SIM) as free drugs and in liposomes. Cell lines were treated with various 
concentrations of SIM, DOX or both drugs, as free or liposomal drugs for 24 or 48 hours. 
Between 30 and 400 cells were counted for each concentration to find the fraction of live cells. 
A: MCF-7 cells incubated for 24 hours. B: MCF-7 cells incubated for 48 hours. This group did 
not receive treatment with the lowest SIM concentration, which is marked with an X. C: H9C2 
cells incubated for 24 hours. Control A is cells in medium and control B is cells in medium 
diluted with 10% PBS. ***: P<0.001 and **: P<0.005 significance relative to control A. 
Significance is found using one-way ANOVA with LSD post hoc tests.  
 
Table 5.2: Statistics from cell viability assays. Statistics comparing the fraction of live MCF-7 
and H9C2 cells in the cell viability assays after incubation for 24 or 48 hours with free or 
liposomal doxorubicin (DOX), simvastatin (SIM) or both drugs. The concentration of 
conditions are in µM and grey condition background are liposomal drugs, while the conditions 
with white background are free drugs. Ctrl A is cell medium and Ctrl B is medium diluted in 
10% PBS. Significance levels are obtained by doing one-way ANOVAs with LSD post hoc test. 

























































































































A) MCF-7 24-hour test
















































































































Ctrl A  n.s. n.s. n.s. n.s. n.s. *** *** *** n.s. n.s. n.s. n.s. n.s. *** *** *** n.s. 
Ctrl B n.s.  n.s. n.s. n.s. n.s. *** *** *** n.s. n.s. n.s. n.s. n.s. *** *** *** n.s. 
15 DOX 
4.67 SIM 
n.s. n.s.  n.s. n.s. n.s. *** *** *** n.s. n.s. n.s. n.s. n.s. *** *** *** n.s. 
5 DOX 
1.51 SIM 
n.s n.s n.s  n.s. n.s. *** *** *** n.s. n.s. n.s. n.s. n.s. *** *** *** n.s. 
2.5 DOX 
0.71 SIM 
n.s n.s n.s n.s  n.s. *** *** *** n.s. n.s. n.s. n.s. n.s. *** *** *** n.s. 
0.5 DOX 
0.15 SIM 
n.s n.s n.s n.s n.s  *** *** *** n.s. n.s. n.s. n.s. n.s. *** *** *** n.s. 
15 DOX *** *** *** *** *** ***  n.s. *** *** *** *** *** *** n.s. n.s. *** *** 
5 DOX *** *** *** *** *** *** n.s.  *** *** *** *** *** *** n.s. n.s. *** *** 
2.5 DOX *** *** *** *** *** *** *** ***  *** *** *** *** *** *** *** *** *** 
0.5 DOX n.s n.s n.s n.s n.s n.s. *** *** ***  n.s. n.s. n.s. n.s. *** *** *** n.s. 
4.67 SIM n.s n.s n.s n.s n.s n.s. *** *** *** n.s.  n.s. n.s. n.s. *** *** *** n.s. 
1.51 SIM n.s n.s n.s n.s n.s n.s. *** *** *** n.s. n.s.  n.s. n.s. *** *** *** n.s. 
0.71 SIM n.s n.s n.s n.s n.s n.s. *** *** *** n.s. n.s. n.s.  n.s. *** *** *** n.s. 
0.15 SIM n.s n.s n.s n.s n.s n.s. *** *** *** n.s. n.s. n.s. n.s  *** *** *** n.s. 
15 DOX 
4.67 SIM 
*** *** *** *** *** *** n.s n.s. *** *** *** *** *** ***  * *** *** 
5 DOX 
1.51 SIM 
*** *** *** *** *** *** n.s. n.s. *** *** *** *** *** *** *  *** *** 
2.5 DOX 
0.71 SIM 
*** *** *** *** *** *** *** *** *** *** *** *** *** *** *** ***  *** 
0.5 DOX 
0.15 SIM 
n.s. n.s. n.s. n.s. n.s. n.s. *** *** *** n.s. n.s. n.s. n.s. n.s. *** *** ***  
 


















































Ctrl A  n.s. *** n.s. n.s. n.s. *** *** *** n.s. n.s. n.s. n.s. *** *** *** n.s. 
Ctrl B n.s.  *** n.s. n.s. n.s. *** *** *** n.s. n.s. n.s. n.s. *** *** *** n.s. 
15 DOX 
4.67 SIM 
*** ***  *** *** *** *** *** *** ** *** *** *** *** *** *** ** 
5 DOX 
1.51 SIM 
n.s n.s ***  n.s. n.s. *** *** *** n.s. n.s. n.s. n.s. *** *** *** n.s. 
2.5 DOX 
0.71 SIM 
n.s n.s *** n.s  n.s. *** *** *** n.s. n.s. n.s. n.s. *** *** *** n.s. 
0.5 DOX 
0.15 SIM 
n.s n.s *** n.s n.s  *** *** *** n.s. n.s. n.s. n.s. *** *** *** n.s. 
15 DOX *** *** *** *** *** ***  n.s. *** *** *** *** *** n.s. n.s. *** *** 
5 DOX *** *** *** *** *** *** n.s.  *** *** *** *** *** n.s. n.s. *** *** 
2.5 DOX *** *** *** *** *** *** *** ***  *** *** *** *** *** *** ** *** 
0.5 DOX n.s. n.s ** n.s n.s n.s. *** *** ***  n.s. n.s. n.s. *** *** *** n.s. 
4.67 SIM n.s. n.s *** n.s n.s n.s. *** *** *** n.s.  n.s. n.s. *** *** *** n.s. 
1.51 SIM n.s. n.s *** n.s n.s n.s. *** *** *** n.s. n.s.  n.s. *** *** *** n.s. 
0.71 SIM n.s. n.s *** n.s n.s n.s. *** *** *** n.s. n.s. n.s  *** *** *** n.s. 
15 DOX 
4.67 SIM 
*** *** *** *** *** *** n.s. n.s. *** *** *** *** ***  n.s. *** *** 
5 DOX 
1.51 SIM 
*** *** *** *** *** *** n.s. n.s. *** *** *** *** *** n.s.  *** *** 
2.5 DOX 
0.71 SIM 
*** *** *** *** *** *** *** *** ** *** *** *** *** *** ***  *** 
0.5 DOX 
0.15 SIM 







C) H9C2 24 hour test 
 Condition 


















































Ctrl A  n.s. n.s. n.s. n.s. n.s. *** *** n.s. n.s. n.s. n.s. n.s. n.s. *** *** *** ** 
Ctrl B n.s.  n.s. n.s. n.s. n.s. *** *** n.s. n.s. n.s. n.s. n.s. n.s. *** *** *** * 
15DOX 
4.67SIM 
n.s. n.s.  n.s. n.s. n.s. *** *** n.s. n.s. n.s. n.s. n.s. n.s. *** *** *** *** 
5DOX 
1.51SIM 
n.s n.s n.s  n.s. n.s. *** *** n.s. n.s. n.s. n.s. n.s. n.s. *** *** *** *** 
2.5DOX 
0.71SIM 
n.s n.s n.s n.s  n.s. *** *** n.s. n.s. n.s. n.s. n.s. n.s. *** *** *** ** 
0.5DOX 
0.15SIM 
n.s n.s n.s n.s n.s  *** *** n.s. n.s. n.s. n.s. n.s. n.s. *** *** *** * 
15DOX *** *** *** *** *** ***  *** *** *** *** *** *** *** * *** *** *** 
5DOX *** *** *** *** *** *** ***  *** *** *** *** *** *** n.s. n.s. n.s. * 
2.5DOX n.s. n.s. n.s. n.s. n.s. n.s. *** ***  n.s. n.s. n.s. n.s. n.s. *** *** *** n.s. 
0.5DOX n.s n.s n.s n.s n.s n.s. *** *** n.s.  n.s. n.s. n.s. n.s. *** *** *** ** 
4.67SIM n.s n.s n.s n.s n.s n.s. *** *** n.s. n.s.  n.s. n.s. n.s. *** *** *** *** 
1.51SIM n.s n.s n.s n.s n.s n.s. *** *** n.s. n.s. n.s.  n.s. n.s. *** *** *** *** 
0.71SIM n.s n.s n.s n.s n.s n.s. *** *** n.s. n.s. n.s. n.s.  n.s. *** *** *** *** 
0.15SIM n.s n.s n.s n.s n.s n.s. *** *** n.s. n.s. n.s. n.s. n.s  *** *** *** *** 
15DOX 
4.67SIM 
*** *** *** *** *** *** * n.s. *** *** *** *** *** ***  * * *** 
5DOX 
1.51SIM 
*** *** *** *** *** *** *** n.s *** *** *** *** *** *** *  n.s. * 
2.5DOX 
0.71SIM 
*** *** *** *** *** *** *** n.s. *** *** *** *** *** *** * n.s.  * 
0.5DOX 
0.15SIM 
** * *** *** ** * *** * n.s. ** *** *** *** *** *** * *  
 
 
5.3 Monitoring Toxic Effects on Zebrafish Larvae After Drug Exposure 
5.3.1 The Anesthetic Drug Tricaine does not Affect Heartrate in Zebrafish 
Larvae 
To exclude the possibility that the handling and sedation of the larvae affected the heart rate 
(HR), the HR of zebrafish larvae exposed to tricaine was measured. There was no significant 
change HR in three dpf zebrafish larvae exposed to 0.2 mg/mL tricaine for 10- or 40-minutes 







Figure 5.9: The effect of the anesthetic drug 
tricaine on zebrafish larvae HR. Zebrafish 
larvae at three days post fertilization were 
placed in 0.2 mg/mL tricaine dissolved in 
embryo water (n=12). HR of the zebrafish 
larvae was observed after 10- and 40-minutes 
and calculated to beats per minute (bpm). n.s.: 
not significant change using paired-sample 




5.3.2 Cardiotoxicity of Free and Liposomal DOX on Zebrafish Larvae 
To see whether a cardiotoxic effect of DOX could be observed in zebrafish larvae, they were 
intravenously injected with 1.9 ng free or liposomal DOX, their HR examined and compared 
with larvae injected with empty liposomes and PBS. In addition to HR, physical observations 
as pericardial effusion (PCE) were observed. Figure 5.10 B and C illustrates how these 
injections caused a decrease in HR in the recipients of free DOX (P < 0.001) and empty 
liposomes (P < 0.005). In the recipients of PBS and DOX liposomes, no change in HR was 
observed (Figure 5.10 A and D). In addition, PCE was observed in five out of 11 recipients of 
free DOX. This effect is illustrated in Figure 5.10 E-G. For DOX liposomes, two out of nine 
larvae were observed with PCE and for the control groups one of ten in the PBS group and two 














































































































Figure 5.10: The effect of doxorubicin (DOX) on zebrafish larvae heart. PBS (n=10), empty 
liposomes (n=21), 1.9 ng free DOX (n=11) or 1.9 ng liposomal DOX (n=9) was injected into 
the posterior cardinal vein (PCV) of 72 hpf zebrafish larvae. All larvae were sedated in 0.2 
mg/mL tricaine prior to injection and observation. The larvae HR was observed prior to 
injection and after 24 hours. A: HR of zebrafish larvae injected with PBS. No significant (n.s.) 
change after 24 hours. B: HR of zebrafish larvae injected with empty liposomes without DOX. 
Significant decrease at P < 0.005 (**) in HR after 24 hours C: HR of zebrafish larvae injected 
with free DOX. Significant decrease at P < 0.001 (***) in HR after 24 hours. D: HR of zebrafish 
larvae injected with DOX liposomes, with n.s. decrease after 24 hours. Statistical significance 
calculated using paired-sample t-test. E-G illustrate pericardial effusion (PCE) in zebrafish 
larvae treated with 1.9 ng free DOX. E: No visible PCE. F: A mild PCE. G: A more advanced 
PCE. White arrows point to the heart of the zebrafish larvae while black arrow point to the 
pericardial sac. H: Fraction of recipients with PCE in each treatment. The images were 
obtained using a Leica M205 stereo microscope.  
 
5.3.3 The Effects of SIM on Zebrafish Embryo and Larvae 
As SIM was to be tested as a cardioprotective drug in DOX-treatment, effects of SIM on 
zebrafish embryo and larvae was examined. First, lethality of the drug dissolved in embryo 
water was determined. Zebrafish embryos at 30 hpf were exposed to SIM-concentrations from 
9.56 nM to 9.56 µM for 24 and 48 hours and observed. Larvae exposed to 0.96 and 9.56 µM 
SIM were all dead and still inside their chorions after 24 hours. For the larvae exposed to 95.6 
nM SIM, five of ten larvae were dead after 24 hours, the dead larvae were still in their chorions. 
Following 48 hours of exposure, all ten larvae in 95.6 nM SIM-group were dead. With the 
lowest concentration of 9.56 nM SIM, no lethality was observed after 24 hours, and all larvae 
were hatched. However, after 48 hours, three out of nine larvae were dead. In the control group, 
exposed only to embryo water, all larvae were alive after 48 hours (Figure 5.11). 
 
In a second test, older zebrafish larvae at 48 hpf were exposed to the same concentrations as in 
the section above for 48 hours. In this test the only group that showed increased lethality was 
the group receiving 9.56 µM SIM, where 50% of the larvae were dead following 48 hours 
incubation. For the larvae that received 0.96 µM SIM, no lethality was observed, but PCE was 
observed in one larva. Neither PCE nor death was observed in the group exposed to 95.6 nM 







Figure 5.11: Lethality of zebrafish larvae exposed to simvastatin (SIM) dissolved in embryo 
water. SIM was dissolved in embryo water in concentrations from 9.56 nM to 9.56 µM. 
Zebrafish embryos at 30 hours post fertilization (hpf), n=9-10, were exposed and lethality 
observed after 24 and 48 hours. Zebrafish larvae at 48 hpf (n=10) were exposed to the same 
concentrations and exposed for 48 hours before observation. No zebrafish larvae in the control 
groups were dead after 48 hours.  
 
Next, 72 hpf zebrafish larvae were exposed to SIM in embryo water and HR examined after 24 
hours. The larvae were placed in SIM concentrations ranging from 4.78 nM to 95.6 nM in 
embryo water, and the control group in embryo water. SIM concentrations up to 38.4 nM did 
not affect HR after 24 hours, but the zebrafish larvae exposed to 95.6 nM SIM had a decreased 
HR to 87.5% (P < 0.001) relative to control (Figure 5.12). PCE was observed in eight out of ten 
zebrafish larvae in the group receiving 95.6 nM SIM, while in one of ten zebrafish larvae 
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Figure 5.12: Cardiac effects of simvastatin (SIM) on zebrafish larvae. A:Heart rate (HR) of 
96 hpf zebrafish larvae treated for 24 hours with 4.78 to 95.6 nM SIM dissolved in embryo 
water. Control group were in pure embryo water, and their HR is illustrated as a horizontal 
line with standard deviation (std.dv.) as dotted lines. ANOVA with LSD post hoc tests was used 
to find significant change in HR of the treated zebrafish larvae (***: P<0.001). B: Percentage 
of zebrafish larvae with pericardial effusion (PCE) for each concentration after 24 hours. n=10 
for all groups. 
 
Statins are known to cause adverse effects affecting the muscles, causing for instance muscle 
pain or rhabdomyolysis (37). Therefore, a preliminary test on the possible effect of SIM on 
zebrafish larvae muscle fiber was investigated. Zebrafish larvae at 48 hpf were exposed to SIM 
concentrations ranging from 9.56 nM to 9.56 µM for 24 hours before muscle fibers in the 
ventral and dorsal parts of the tail were observed. Figure 5.13 shows images of the muscles 
after exposure to SIM. More tests are necessary but note that in images D and E in Figure 5.13 
has a higher contrast in the muscle fiber as well as the tail being less transparent relative to the 
zebrafish larvae receiving lower SIM concentrations where the muscle is smoother and more 
translucent.  
 


















































Figure 5.13: Zebrafish tail muscle fibers after treatment with simvastatin (SIM) in embryo 
water. Images of 72 hours post fertilization zebrafish larvae after 24 hours of treatment with 
SIM dissolved in embryo water. A: Control, only exposed to embryo water. B: 9.56 nM SIM 
exposure. C: 95.6 nM SIM exposure. D: 0.96 µM SIM exposure. E: 9.56 µM SIM exposure. The 
arrows point to either dorsal or ventral skeletal muscles to indicate changes in muscle fibers. 
Images obtained using a Leica M205 stereo microscope. Scale bar: 100 nm.  
 
5.3.4 Exploring SIM as a Cardioprotective Agent in DOX Treatment 
In the first experiments conducted to find whether SIM offered cardioprotective effect in DOX 
treatment of zebrafish larvae, the larvae were injected with 1.9 ng DOX and placed in embryo 
water with or without 9.56 nM SIM. Reduced HR was observed in DOX injected larvae both 
with and without being exposed to SIM, P<0.01 and P<0.005, respectively (Figure 5.14 A). In 
the group receiving only DOX, there was a higher fraction of zebrafish larvae dead and with 
PCE after 24 hours relative to those treated with SIM post injection. No zebrafish larvae were 
dead nor had PCE in the control or the SIM group (Figure 5.14 B). 
 
A) Control B) 9.56 nM SIM C) 95.6 nM SIM
D) 0.96 µM SIM E) 9.56 µM SIM









Figure 5.14: Toxic effects of doxorubicin (DOX) and simvastatin (SIM) on zebrafish larvae 
heartrate and survival. A: Heartrate of 72 hours post fertilization zebrafish larvae observed 
24 hours post injection with 1.9 ng DOX and/or being placed in 9.56 nM SIM dissolved in 
embryo water post injection. The control group was placed in embryo water. n=10-11 for all 
groups. Significance **: P<0.01, ***: P<0.005 found by one-way ANOVA with LSD post hoc 
test. Unless otherwise mentioned, no significance was observed. B: Percentage of dead 
zebrafish larvae and zebrafish larvae with pericardial effusion 24 hours post injection and/or 
SIM exposure. 
 
Next, three dpf zebrafish larvae were injected with PBS, free DOX, DOX liposomes, SIM 
liposomes or SIM-DOX liposomes and the toxic effects were observed after 24 hours. Two 
zebrafish larvae were observed to have PCE in the group receiving free DOX, and one in the 
SIM-DOX liposome group.While there was a significant decrease in HR for the DOX injected 
larvae relative to control (P < 0.001), there was an increase for those injected with SIM 
liposomes (P < 0.001). For the zebrafish larvae injected with DOX liposomes or DOX-SIM 
liposomes no change in HR was observed after 24 hours (Figure 5.15 A).  
 
Two dpf zebrafish larvae were also injected with PBS, DOX, DOX liposomes or SIM-DOX 
liposomes and observed after 48 hours. After 48 hours a decrease in HR was observed in the 
larvae injected with free DOX, DOX liposomes and SIM-DOX liposomes (Figure 5.15). One 
larvae was dead in the DOX liposome group, while all larvae that recieved free DOX, PBS and 
SIM-DOX liposomes were alive. PCE was observed in one of the zebrafish that was injected 
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Figure: 5.15: Cardiac and lethal effects on zebrafish larvae after injections with doxorubicin 
(DOX) and simvastatin (SIM) as free drug and liposomes. Heartrate (HR), pericardial 
effusion (PCE) and death in zebrafish larvae after injection with PBS, free DOX, DOX 
liposomes, SIM liposomes or SIM-DOX liposomes (n=10-12). The drug doses were 1.9 ng DOX 
and 0.38 ng SIM. A: The HR of four days post fertilization (dpf) zebrafish larvae observed 24 
hours post injection (hpi), B: The HR of four dpf zebrafish larvae injected and observed 48 hpi. 
One-way ANOVA with LSD post hoc test was used and significance being **: P<0.005 or ***: 
P<0.001. There was no significant change unless otherwise is mentioned. C: Fractions of dead 
zebrafish larvae or zebrafish larvae with PCE 24 hpi D: Fractions of dead zebrafish larvae or 
zebrafish larvae with PCE 48 hpi. 
 
5.4 Distribution of Liposomes in Zebrafish Larvae Circulation 
The green fluorescent phospholipid ATTO-488 DPPE was incorporated into DOX liposomes 
which was injected into the PCV of two dpf zebrafish larvae. This made it possible to visualize 
and inspect how the fluorescent liposomes was distributed in the zebrafish larvae over the 
course of two days (Figure 5.16). Two to four hours post injection, the liposomes were observed 
in the entire zebrafish larvae vasculature, including the smaller vessels in the head and along 
the tail of the larvae (Figure 5.16 A). The vascular fluorescence became less clear one- and two 
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days post injection (dpi) as more of the fluorescence was observed extravascular and seemed 
to accumulate in spots, but there was still fluorescence present in the vasculature (Figure 5.16). 
 
 
Figure 5.16: Zebrafish larvae injected with fluorescent liposomes. ATTO-488 DPPE labeled 
liposomes with doxorubicin were injected in the posterior cardinal vein of two days post 
fertilization zebrafish larvae. The figure displays representative images of one injected larva. 
A: The larva two to four hours post injection. B: One day post injection (dpi). C: Two dpi. 
Images obtained as z-scans in an Andor Dragonfly 505 confocal microscope. Scale bar: 500 
µm. 
 
5.5 Injections of MCF-7 Cells in Zebrafish Larvae 
To observe how MCF-7 cancer cells acted inside the zebrafish larvae, the cells were stained 
with the cell stains, injected in the yolk sac or in PCV of zebrafish larvae and observed once 
daily over one to two days. The first cell stain tested on MCF-7 was CTG. Figure 5.17 show 
the clearest images obtained with CTG at a few hours post injection. However, the fluorescence 








Figure 5.17: CellTracker™ green (CTG) stained MCF-7 cells in zebrafish yolk sac. Zebrafish 
larvae at one day post fertilization were dechorionated and injected with CTG stained MCF-7 
cells in the yolk sac. The images were obtained as z-scans at the day of injection. A: The 
zebrafish yolk sac and injected cells. B: The injected cells in the yolk sac. The images were 
obtained in an Andor Dragonfly 505 confocal at 20x magnification. Scale bar: 50 µm. 
 
Previously, another cell tracker, DiI, gave good results when injecting human acute myeloid 
leukemia cells MOLM-13 into zebrafish larvae (see Appendix, Supplementary Figure 4). 
Staining of MCF-7 cells with DiI stain was therefore tested. 
 
Figure 5.18 shows a zebrafish larva injected in the yolk sac with DiI stained MCF-7 cells from 
between two- and four hpi, and one- and two dpi. At two to four hpi, the fluorescent signal was 
only visible in the yolk sac, but after one- and two- dpi, the signal also had spread to the tail of 
the zebrafish larvae (Figure 5.18). In this experiment three out of nine total yolk sac injected 
zebrafish larvae had signal redistributed to the tail at one day post injection (Zebrafish larvae 
with MCF-7 cells in the yolk sac over two days without spreading is illustrated in 
Supplementary Figure 5). Table 5.3 show the number and area of fluorescent events observed 
in Figure 5.18. Both the area and number of events were seen to increase from hours post 









Figure 5.18: Zebrafish larvae injected into the yolk sac with DiI stained MCF-7 cells. 
Representative images of a two days post fertilization zebrafish larva injected with DiI stained 
MCF-7 cells into the yolk sac with signal spreading to the tail at one day post injection (dpi). 
A: The zebrafish larva yolk sac imaged between two to four hours post injection (hpi). B: One 
dpi, with arrows pointing to fluorescent signal in tail. C: Two dpi with arrows illustrating 
fluorescent signal in the tail. D: Fluorescence in the yolk sac two to four hpi. E: Fluorescence 
in the yolk sac one dpi. F: Fluorescence in the yolk sac two dpi. G: Fluorescence in tail one 
dpi. H: Fluorescence in tail two dpi. The z-scans were obtained at 10x magnification in an 
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Table 5.3: Fluorescence in the Figure 5.18 zebrafish larva. Fluorescent events as number and 
area in the zebrafish larva at zero, one- and two days post injection of MCF-7 cells into the 
yolk sac. Analyzed using FIJI software.  
Days post injection 0 1 2 
Fluorescent events 18 47 56 
Area of fluorescence (µm2) 3401 3542 8754 
 
Next, two dpf zebrafish larvae were injected intravenously into the PCV with DiI stained MCF-
7. Two to four hpi, the fluorescent signal could be observed in most parts of the zebrafish 
vascular system. After one and two days the signal was mainly observed in the area of the dorsal 
aorta (DA) and PCV, as well as the ventral parts of the yolk sac, and was observed to be more 
condensed compared to the image from the day of injection (Figure 5.19). These observations 
were done for all three PCV injected larvae in the experiment. Quantification of fluorescent 





















Figure 5.19: Intravenously injected MCF-7 cells in a zebrafish larva. Representative images 
of a zebrafish larva injected with DiI stained MCF-7 into the posterior cardinal vein at two 
days post fertilization. A and D: The zebrafish larva two to four hours post injection. B and E: 
The zebrafish larva one day post injection (dpi). C and F: The zebrafish larva two dpi. The 
images were obtained as z-scans at 10x magnification with an Andor Dragonfly 505 confocal. 
Scale bar: 200 µm.  
 
Table 5.4: Number of fluorescent events in the zebrafish larvae from Figure 5.19. 
Fluorescent events at zero, one- and two days post injection into the posterior cardinal vein of 
MCF-7 cells stained with DiI. Particles analyzed using FIJI software.  
Days post injection 0 1 2 
Fluorescent events 251 123 55 
Area of fluorescence (µm2) 4000 3654 2024 
 
In another experiment, two 48 hpf zebrafish larvae were injected intravenously with DiI stained 
MCF-7 and observed to have a much higher number of fluorescent signals at one dpi relative 
to two to four hours post injection. One of these zebrafish larva is visualized in Figure 5.20. In 
Table 5.5 it is illustrated that more than 20 times as many fluorescent events were observed at 
one dpi relative to two to four hpi, and more than eight times as large area is covered by the 
fluorescence in the zebrafish larvae. These larvae were unfortunately not visualized at two dpi 
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Figure 5.20: Zebrafish larva injected intravenously with DiI stained MCF-7. A zebrafish 
larva injected into the posterior cardinal vein with DiI stained MCF-7 cells at two days post 
fertilization. A and C: The zebrafish larva two to four hours post injection with the injected 
cells visualized only at the injection site. B and D: The zebrafish larva one day post injection 
where the fluorescent signal has spread to both tail and yolk sac region of the larva. Arrows 
point to the injection site. Images obtained as z-scans at 10x magnification in an Andor 
dragonfly 505 confocal microscope. Scale bar: 200 µm.  
 
Table 5.5: Fluorescent events from Figure 5.20. The number and area of fluorescent events in 
the zebrafish larva in Figure 5.20 at the day of injection and one day post injection. Particles 
analyzed using FIJI software. 
Days post injection 0 1 
Fluorescent events 4 98 
Area of fluorescence (µm2) 1261 10170 
 
Next, the zebrafish larvae were injected with both DiI and CTG stained MCF-7 cells in the 
PCV. Longer incubation time for cells with the CTG stain was attempted to see whether the 
staining remained visible for longer after injection. However, while the DiI stain was clearly 
visible after two days, CTG was visible at two to four hours post injection and barely visible in 
a few larvae at one dpi (Figure 5.21 and Figure 5.22). In Figure 5.21, at the day the of injection, 
eleven fluorescent events are seen with both green and red fluorescence and three are seen with 
only green fluorescence. At one dpi, only one spot is seen with both green and red fluorescence, 
and one with only green fluorescence. In Figure 5.22, 14 events are seen with both fluorescent 
stains at a two to four hpi, while only two events are seen with both DiI and CTG stains at one 
dpi. One particle is observed with only CTG stain in the image, but this is outside the zebrafish, 
probably adhered to the bottom of the well. The zebrafish larva in Figure 5.22 was not imaged 
at two dpi. In Figure 5.21 A, a larger green fluorescent signal is observed dorsal to the yolk sac. 









Figure 5.21: Zebrafish larva injected with CellTracker Green CMFDA (CTG) and DiI 
labeled MCF-7. MCF-7 cells stained with both DiI and CTG was injected into the posterior 
cardinal vein of two days post fertilization zebrafish larvae. The figure shows representative 
images of one of the injected larvae. A: The larva visualized two to four hours post injection 
with both red DiI and green CTG signal present. B: One day post injection where two cells are 
still visible with green fluorescence. C: Two days post injection with just the red fluorescence 
still visible. Arrows point to cells inhabiting both green and red fluorescence. Images obtained 
as z-scan with an Andor Dragonfly 505 confocal at 10x magnification. Scale bar: A: 200 µm, 
B and C: 300 µm.  
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Figure 5.22: Zebrafish larva injected with CellTracker Green CMFDA (CTG) and DiI 
labeled MCF-7. MCF-7 cells stained with both DiI and CTG and injected into the posterior 
cardinal vein of two days post fertilization zebrafish larvae. A: The larva visualized two to four 
hours post injection with both red DiI and green CTG signal present. B: Zebrafish larva 
visualized at one day post injection where two cells are still visible with green fluorescence. 
Yellow arrows point to clusters of three cells with both cell stains. White arrows point to single 
cells with both cell stains. Images obtained as z-scan in an Andor Dragonfly 505 confocal at 
10x magnification. Scale bar: 400 µm.  
 








In order to see if intravenously injected liposomes interacted with cancer cells, zebrafish larvae 
at two dpf was injected with DiI stained MCF-7 cells in the yolk sac and ATTO-488 DPPE 
labeled DOX liposomes in PCV. Both cells and liposomes were observed in the confocal 
microscope, but the liposomes did not accumulate to the area of the cancer cells in the yolk. 
When counting the area and number of fluorescent events, both were seen to approximately 
double over after one day (Figure 5.23 and Table 5.6).  
 
 
Figure 5.23: Zebrafish injected with doxorubicin (DOX) liposomes and MCF-7. 
Representative images of a zebrafish larva injected with DiI stained MCF-7 cells in the yolk 
sac and green fluorescent ATTO-488 DPPE labeled DOX liposomes in the posterior cardinal 
vein at two days post fertilization. A: Zebrafish larva between two to four hours post injection. 
B: Zebrafish larva one day post injection. Images obtained as z-scan with an Andor Dragonfly 
505 confocal at 10x magnification. Scale bar: 200 µm.  
 
Table 5.6: Fluorescent events from DiI stained MCF-7 cells in zebrafish larvae injected with 
DOX liposomes. The observed DiI fluorescence in the yolk sac from the zebrafish larva in 
Figure 5.23 injected with both MCF-7 cells and DOX liposomes. Particles analyzed using FIJI 
software. 
Days post injection 0 1 
Fluorescent events 17 33 







In this study, free and liposomal DOX and SIM were tested for toxicity in zebrafish larvae and 
in cell assays. The liposomal formulations were observed to be less toxic than equivalent doses 
of free drug, whereas further studies need to be conducted to establish potential cardioprotective 
effects of SIM. Additionally, injection of the human cancer cell line MCF-7 in zebrafish larvae 
was conducted to establish a method for cancer cell transplantation in zebrafish larvae, and the 
fluorescent signal used to stain the cells was observed to grow in number and to redistribute in 
the zebrafish larvae over two days.  
 
In order to obtain consistent results, it was important that the drug content in the liposomes 
were measured exactly. This study used HPLC, which is a reliable method for quantification of 
small organic molecules and drugs. The HPLC chromatogram of DOX showed minor peaks 
directly prior to the elution of DOX (Figure 5.1). The area of these peaks was the same in all 
DOX standard concentrations and therefore likely to be an impurity of the mobile phase or 
solvents used, and not a degradation product from DOX from the stock solution. The standard 
curve obtained had an R2 of 1.00 and was considered sufficient to estimate DOX concentration 
in the liposome samples (Figure 5.1, insert). The first HPLC-test for SIM using the C18 column 
was developed so it was possible to quantify both DOX and SIM in one run. However, this 
method gave poor results with SIM eluting on top of a noisy baseline at the wash of the column 
(Figure 5.2). Using a phenyl-hexyl column took advantage of pi-pi interactions between ring 
structures of SIM (Figure 2.2) and the phenyl residues in the solid phase (123), and a more 
predictable elution of SIM was achieved. In these methods, methanol was used as a mobile 
phase to disrupt the pi-pi interactions which eluted the drug on a baseline with little noise and 
in a narrow, single peak, before wash of the column with ACN. The standard curve had an R2 
of 1.00 and was determined to be good for calculation of liposomal SIM concentration (Figure 
5.3).  
 
The DOX loading in both DOX- and SIM-DOX liposomes was 20% w/w DOX loading relative 
to lipid concentration and the encapsulation efficiency was high with little DOX outside the 
liposomes even before SEC. This is demonstrated by no secondary peaks in Figure 5.4 and 
correlating with other findings (124). Ideally, the liposomes should have been filtered through 
the SEC column after the addition of DOX to ensure that all unencapsulated drug was 





in zebrafish larvae. In Figure 5.4 A, the SEC elution volume of DOX liposomes is compared to 
that of ATTO-488 DPPE liposomes to determine encapsulation. The DOX liposomes were 
found to elute approximately one minute before the fluorescent liposomes. This difference in 
elution volume can be explained by the fact that the column ran dry during the washing process 
after the filtration of the ATTO-488 DPPE liposomes and needed to be repacked. Repacking of 
columns will influence the conditions, such as packing density, and thus travelling length and 
elution volume for the DOX liposomes. However, the DOX liposomes and SIM-DOX 
liposomes were observed to elute in one, narrow peak, and no peaks were observed to elute at 
a later point (Figure 5.4). On the other hand, free DOX eluted as a broad peak starting at eight 
mL, and not fully eluted after 19 mL (Figure 5.4 B). As DOX molecules are much smaller than 
the liposomes, this difference in elution volume was expected, and no overlap between 
fluorescent liposomes and free DOX made it possible to conclude that the observed peaks from 
the SEC of the liposomes were indeed encapsulated drug. Thus, the liposomes were used on 
the zebrafish larvae without an additional SEC filtration after DOX addition. The highest DOX 
concentrations achieved in the liposomes were between 0.45 and 0.5 mg/mL liposomal DOX, 
which allowed for maximum injection dose of 1.9 ng DOX in zebrafish larvae in the study. 
 
In treatment of hyperlipidemia, SIM is administered orally as tablets (37). It was desired to 
produce a liposomal formulation with SIM, which in many cases are designed to minimize 
adverse and toxic effects. A known adverse effect of statins in humans is rhabdomyolysis, 
destruction of skeletal muscle (37). In the study, skeletal muscle in the tail of zebrafish larvae 
exposed to 0.96 and 9.56 µM SIM for 24 hours was observed to become more irregular and 
revealed a higher contrast compared to those exposed to 9.56 and 95.6 nM SIM and control 
(Figure 5.13). However, only a few larvae were observed for each concentration, and more tests 
must be conducted to observe if this effect is typical to SIM exposure. The encapsulation of 
SIM together with DOX in liposomes could allow for the zebrafish larvae to tolerate higher 
concentrations of SIM and achieve cardioprotective effects without risks of rhabdomyolysis. 
Additionally, orally administered SIM has its main mechanism of action in the liver, and little 
drug reaches circulation, making it less suitable as a cardioprotective drug in anthracycline 
therapy (Section 2.1.1). Liposomes with both drugs encapsulated would reach the same cells in 
the body, ensuring the protective effect at the correct site. Further dose-escalation studies with 
SIM liposomes should be done to find MTD in zebrafish larvae, which could be used to find 






Liposome size was measured using DLS, an indirect method for determining size of spherical 
particles. It was considered to use transmission electron microscopy (TEM) to verify the size. 
However, extrusion is a reliable method for liposome production, and the suspensions were 
passed through the smallest filters twice. In addition, due to the covid-19 situation, this analysis 
could not be conducted. Knudsen (114) and Gundersen (125) found, when comparing results 
from DLS and TEM, that the former resulted in larger liposome size relative to what was 
visualized in TEM. Nevertheless, DLS is still regarded as a reliable method to measure 
liposome size. In the present study, the liposomes were found to be approximately 130 nm in 
diameter by DLS. Upon PCV injection of green fluorescent liposomes in zebrafish larvae, the 
fluorescence was observed to be distributed in the entire vascular system, and not observed to 
clog even the small capillaries, as demonstrated in Figure 5.16.  
 
Cell assays were performed to observe toxicity of the produced liposomes and free drugs. The 
results from the WST-1 assay showed poor correlation between signal and the number of 
normal cells observed in the microscope (Appendix, Supplementary Figure 1 and Figure 5.8). 
Several explanations were considered. One possibility was that the cells had extremely high 
metabolic activity, and even a few cells still alive in the wells would be able to convert all WST-
1 to the formazan compound. Another explanation was that there were bacteria growing in the 
wells that were able to convert WST-1 to formazan. However, no bacteria were observed when 
studying the wells in light microscope or in fluorescence microscopy after Hoechst-staining. 
Thus, no good explanation to why the WST-1 assay did not give satisfactory results was found. 
Consequently, assessment of cytotoxic effects of the treatments was done by visual counting of 
the cells and nuclei. The counting process has some drawbacks, it is tedious, and it can be 
difficult to distinguish cells with normal morphology from apoptotic or necrotic cells. Also, 
DOX and Hoechst 33342 both bind in the minor groove of DNA and compete on binding (126). 
Higher free DOX concentrations therefore resulted in weak Hoechst-stained cell nuclei, causing 
difficulties in visualizing the nuclei. Because of this, the nuclei of cells treated with higher 
concentrations of free DOX were observed using a rhodamine fluorescence filter for red 
fluorescence. This made it harder to compare the free DOX treated wells to control wells, which 
were observed using a DAPI filter for blue Hoechst fluorescence. There was a desire to conduct 





incubation, as well as including DOX liposomes in the study but because of the limited 
laboratory time as a result of the covid-19 pandemic this could not be prioritized.  
 
Incubation for 24 hours with SIM-DOX liposomes was found not to affect cell viability for 
either H9C2 or MCF-7 cells (Figure 5.8). After 48 hours incubation, however, decreased 
viability was observed for the MCF-7 cells, but these cells were still more viable than those 
treated with equivalent concentrations of free DOX (Table 5.2). The cells treated with SIM-
DOX liposomes for both 24- and 48 hours also had visible Hoechst 33342 fluorescence, 
indicating that less DOX had entered the nuclei relative to the cells treated free DOX, where 
the Hoechst fluorescence was not visible in the highest concentrations (Figure 5.5-5.7). The 
H9C2 cells showed a higher tolerance to DOX than the MCF-7 cells, where incubation with 5 
and 15 µM rendered all MCF-7 cells dead, whereas 44 and 12% of H9C2 cells were still viable 
in these concentrations, respectively. Additionally, H9C2, but not MCF-7, seemed to benefit 
from co-treatment with SIM in 15 µM DOX concentration since a reduction of death was 
observed in the H9C2 cells (Figure 5.8 and Table 5.2 A and C). These results could indicate 
that during high-dose therapy of DOX, co-therapy with SIM can be beneficial to the heart, while 
not reducing therapeutic response of DOX on cancer cells.  
 
The toxicity of DOX and the potential protective effects of liposomal formulations and SIM 
were tested on zebrafish larvae. Several zebrafish larvae assays testing the toxicity of 
nanoparticular anthracyclines are based on adding drugs or nanoparticles in embryo water, like 
those of Han et al. (16) and Calienni et al. (127). This will not only unnecessarily expose the 
zebrafish skin and gills to toxic drugs, but more importantly, the zebrafish larvae are only able 
to absorb small molecules through diffusion, and the absorption of free drug would happen 
much more efficient compared to liposomal drugs. This would give an overestimated protective 
effect of the liposomal formulation on zebrafish larvae. Additionally, in the clinic, intravenous 
infusions are the administration route of DOX, thus microinjections represent a more realistic 
approach. DOX is, as mentioned in the introduction, known to cause cardiotoxic effects years 
and even decades after treatment, with young age being a risk factor. As we could not observe 
larvae after four dpf, when they start to require feeding, in this study, long-term cardiotoxic 
effects in zebrafish were not investigated. It would have been interesting to observe how DOX 






As tricaine exposure did not affect HR over time (Figure 5.9), sedated larvae were used to study 
cardiotoxicity in the study (Figure 5.10). Free DOX caused a decrease in HR, and an increased 
occurrence of PCE in zebrafish larvae 24 hpi, while liposomal DOX did not affect HR, and the 
incident of PCE was lower. This was to be expected as liposomal DOX is used in the clinic to 
reduce adverse effects. The reduced HR of zebrafish could be associated with the arrythmias 
that is seen in humans as an acute cardiotoxicity of DOX (27). Arrythmias, were not examined 
in the present study, but should possibly be evaluated in further experiments. Additionally, PCE 
and reduced HR could be a result of cell death in the heart after DOX treatment, as observed 
for H9C2 in the cytotoxicity assays, causing the heart to lose integrity, and ultimately leading 
to edema of the pericardium and reduced HR. There were individual differences between the 
larvae within one treatment, both in regards of HR and PCE (Figure 5.10). This reflects the 
situation in humans, where the occurrence and rate of adverse effects of drugs are very 
individual. This also illustrates the power of in vivo models compared to cell-based systems for 
toxicity screenings, and that zebrafish, and especially larvae, can be an inexpensive model for 
drug toxicity screenings and discovery of rare adverse effects. In the test, injection of PBS did 
not change HR, but unexpectedly, reduced HR was observed for the larvae injected with empty 
liposomes (Figure 5.10). These injections were intended as a control for DOX liposomes and 
giving that DOX liposomes did not decrease HR it seemed strange that liposomes with no drug 
added would. Damage to the heart could have been caused by too high injection pressure in the 
test which further could have reduced HR of the larvae in the empty liposome group.  
 
As SIM is practically insoluble in aqueous solutions (38), the drug alone could not be injected. 
However, the zebrafish larvae were exposed to SIM dissolved in embryo water, or as injections 
with SIM liposomes. When adding SIM to the embryo water, it was observed that higher 
concentrations were harmful to the larvae, causing death, PCE and reduced HR (Figure 5.11 
and 5.12). Injection of 0.38 ng SIM liposomes increased HR of zebrafish larvae after 24 hours 
(Figure 5.15 A). Increased HR in humans or in other zebrafish studies due to statin therapy is 
not observed, and there could be other factors like high injection pressure in the control group 
causing it to have reduced HR, affecting the results. Campos et al. hypothesized that reduction 
in HR after SIM treatment could be caused by low cholesterol and found that treatment with 
LDL cholesterol together with SIM did not alter HR, while SIM alone gave a significant 
reduction when exposed from 6 to 24 hpf (128). They did not, however, provide further 





of statins are recommended in pregnancy where cholesterol is crucial to development of the 
fetus (37, 129). Maerz et al. related heart defects in zebrafish larvae treated with atorvastatin 
from 10 to 48 hpf to those of humans with hypocholesterolemic syndromes. They linked 
dysfunctional cilia to be caused by low cholesterol, further causing several developmental 
malformations, including of the heart (130). In addition to decreased HR and PCE after 
treatment with atorvastatin, Maerz et al. found physical alterations including smaller atrium and 
ventricles and elongation of the heart in the treated zebrafish larvae. This supported their theory 
of lowered cholesterol levels in embryogenesis causing defects in the formation of the heart, 
which further could affect HR and give PCE (130). Campos et al. also observed the effect of 
SIM treatment early in embryonic development, where treatment from six hpf gave more 
advanced developmental defects relative to embryos treated from eleven hpf (128). Figure 5.11 
shows that larvae exposed to SIM dissolved in embryo water from 48 hpf had a higher survival 
when exposed to the same concentrations of SIM for 48 hours compared to embryos exposed 
from 30 hpf. Taken together, SIM is observed to be more toxic in an early developmental stage 
of zebrafish larvae, likely because of cholesterol-lowering effects, which is also a risk in human 
embryonic development.  
 
Further, the combination of SIM with DOX was explored, both as free drug dissolved in the 
embryo water post DOX injection, and by co-injections of both drugs in liposomes. SIM did 
not provide further protection against decreased HR than what was achieved by liposomal 
formulation of DOX. However, there was observed lower frequency of PCE and death in the 
SIM-DOX co-treated larvae, compared to those treated with free DOX alone in the test with 
SIM dissolved in embryo water post DOX injection (Figure 5.14). H9C2 cells had increased 
viability in the highest concentration of DOX and SIM together, relative to high dose DOX 
alone. It might be necessary with higher SIM concentrations to observe cardioprotective effects 
in DOX treatment in zebrafish. Higher doses of free SIM, however, gave toxic effects when 
dissolved in embryo water. Therefore, higher concentrations of SIM liposomes should be 
produced. Escalating doses of SIM liposomes injected in zebrafish larvae could be used to find 
MTD, and then used in SIM-DOX liposomes to see if this could provide a cardioprotective 
effect in zebrafish larvae.  
 
When comparing injections of free DOX, DOX liposomes and SIM-DOX liposomes injected 





treatments gave equal reduction in HR (Figure 5.15 A and B). The HR conserving effect seen 
at 24 hours could be related to the liposomal formulation alone. Liposomal drugs would not be 
instantaneously available to cells and tissues like free drugs. This could explain why DOX- and 
SIM-DOX liposomes also gave reduction in HR and reduced viability of MCF-7 cells in the 
cell assays following 48 hours incubation, while not after 24 hours (Figure 5.8, 5.15 and Table 
5.2). More toxicity assays comparing free and liposomal DOX on zebrafish larvae should have 
been conducted over a 48-hour period as well as 24 hours since DOX- and SIM-DOX liposomes 
were observed to be more toxic after 48 hours of incubation (Figure 5.15). SIM is a prodrug, 
and it is not known whether the cardioprotective effect requires the active component of the 
drug, which could be a limitation in the drug being encapsulated in liposomes. However, a 
cardioprotective effect was observed in the H9C2 cardiomyoblast cells upon co-treatment of 
SIM and DOX, so it is assumed that this active component is not necessary or that SIM also 
can be converted to its active form in non-hepatic cells.   
 
In order to find whether tissues could be affected by liposomal drugs, it was important to know 
the fate of the intravenously injected liposomes. When injecting ATTO-488 DPPE labeled 
DOX liposomes in zebrafish larvae, the liposomes were initially observed to flow free in the 
vascular system, but already in the first images at a two to four hpi, the green fluorescence 
tended to accumulate in spots along the vasculature, as likely to be in macrophages. Evensen et 
al. illustrated this in one study, where pegylated liposomes were seen to be continuously 
removed from the circulation and entering macrophages over 72 hours (131). The liposomes in 
that study appeared to be completely cleared from the circulation after 70 hours, while the 
fluorescence of liposomes was still present in macrophages at this point (131). Following one 
and two dpi in the present study, the number and intensity of the fluorescent spots increased, 
but there was still green fluorescence observed intravascularly at two dpi, indicating that intact 
liposomes were still in circulation after two days. The use of liposomal formulations of DOX 
will increase plasma circulation and give a larger area under the curve compared to equivalent 
doses of free DOX (132). At the same time a lower peak concentration of available drug in the 
body could help avoid adverse effects, since DOX will be slowly released from the liposomes, 
and not be instantaneously available. In the study, the cardioprotective effect of injected 
liposomes on HR was seen to decline 48 hpi, following the decline of intravascular green 






Both yolk sac and PCV injections of MCF-7 cells were performed in the study, and the 
distribution of injected cells differed based on injection method (Figure 5.18 and 5.19). In 
literature, cancer cells are seen to metastasize after yolk sac injection in zebrafish larvae already 
at 24 hpi, and that cancer cell lines with higher migratory capacity more often metastasize out 
of the yolk sac (133). In other studies, MCF-7 cells have shown little invasive and metastasizing 
capacity in zebrafish (134, 135). In the present study, the cells usually remained in the yolk sac 
over the course of two days after yolk sac injections. However, in three zebrafish larvae the 
fluorescent signal was in fact observed in the tail region of the zebrafish larvae at one and two 
dpi (Figure 5.18). In Figure 5.18 the area of fluorescent signal is seen to increase over two days 
as the cells spread across the yolk sac and tail of the larvae (Table 5.3). In the intravenously 
injected larvae, the cells were observed to spread throughout the vascular system already two 
to four hpi, before accumulating ventrally in the duct of Cuvier and along the line of the DA 
and PCV at one and two dpi with the area of fluorescent signal decreasing as the fluorescence 
seemed to concentrate (Figure 5.19 and Table 5.4). In the study, PCV injections of cells did 
more often result in visible fluorescence in the zebrafish larvae compared to yolk sac injections. 
However, the yolk sac injections were interesting as they allowed for mapping the metastasizing 
potential of the cancer cells. Further microscopic analyses would have been interesting to 
observe whether the cells adhered to the vasculature and started to form tumors or migrated out 
of the vasculature. Additionally, injections of both liposomes and MCF-7 in the PCV could 
have allowed for observations of cell interactions with liposomes. By observing these features, 
it can be studied whether cancer cell lines behave in zebrafish larvae after xenograft 
transplantation as they are expected in humans.  
 
As mentioned in the introduction, zebrafish does not have an adaptive immune system at two 
to four dpf, but they do have an innate immune system including for instance macrophages 
(136). One difficulty when injecting cells in zebrafish larvae was to verify if the fluorescent 
events observed were cells, and not cell stain consumed by macrophages as they ingest debris 
of dead cancer cells, which then were transported around the zebrafish larvae. Evensen et al. 
observed that fluorescent liposomes were consumed by macrophages (131), and the fluorescent 
events in the tail regions of the larvae injected with MCF-7 cells in Figure 5.18 and 5.19 
appeared to settle at the same area as the green fluorescent liposomes in Figure 5.16, which 
likely are taken up by macrophages. The zebrafish larvae visualized in Figure 5.20 has a very 





cell remains being consumed by macrophages, also picking up the fluorescence could explain 
this. Another explanation is that the fluorescent event observed at two to four hpi in Figure 5.20 
consist of more cells than apparent in the microscope, which later will spread along the larvae 
by the blood. In future studies, it would be interesting to fixate and section the larvae for 
histological analyzes. By for instance using fluorescent monoclonal antibodies binding 
specifically to human cells it could be determined whether the spots located in the medial tail 
region in fact were human MCF-7 breast cancer cells metastasizing in the larvae. This was 
demonstrated by Lee et al. who labeled human melanoma cells using monoclonal antibodies to 
distinguish these cells from zebrafish cells (137). Further, the use of genetically manipulated 
zebrafish with mutations like fluorescent endothelium or macrophages could give better 
indications of the cancer cells whereabouts relative to the vasculature and interactions with 
macrophages (131, 134).  
 
Two types of cellular stains, DiI and CTG, were used in the study to visualize injected cells in 
the zebrafish larvae. One of the main benefits with CTG is that the stain is non-fluorescent until 
it has entered the cells, where it is converted into the fluorescent product (Section 3.8). 
Consequently, all fluorescence observed in confocal microscope is intracellular. Additionally, 
in this study the images obtained with CTG allowed for clearer visualization of single cells 
(Figure 5.17), while the fluorescent signals obtained with DiI was so strong that it was difficult 
to distinguish separate cells located close together (Figure 5.18). The DiI stain also caused the 
injection medium to be lightly fluorescent, giving weak fluorescent signals in the area around 
the cell injections in the zebrafish larvae. This made quantification of the cell mass inside 
zebrafish larvae difficult, as this background fluorescence had to be filtered out. One clear 
disadvantage with CTG however, was the short duration of the signal visible in the microscope. 
In the first test using CTG stain the cells were only visible at the day of injection (Figure 5.17). 
In the second test the incubation time of the staining was doubled. That made it possible to 
observe some cells at one dpi as well, but the signal was very weak (Figure 5.21 and 5.22). The 
stain could be more light sensitive than the DiI stain, and care had to be taken to protect the 
larvae from light. Optionally, too few CTG molecules were present in cells after cell division 
to be detected. Strouse et al. found CTG to be a substrate for both multidrug resistance protein 
1 and breast cancer resistance protein (138), and CTG could have been pumped out of the cells 
by such proteins. This would not be a problem with DiI which is a cell membrane stain, and not 






Due to the covid-19 pandemic, some tests had to be terminated before completion as the 
university was closed, and some tests that were planned could not be conducted. In the present 
study, the experiments that were most affected by the lock-down were the planned injections 
of both MCF-7 cells and DOX liposomes to observe therapeutic effect. The plan was to do a 
larger study with MCF-7 cells injected both in the yolk sac and PCV, and thereafter inject free 
DOX and DOX liposomes. From this, we could observe whether free DOX and DOX liposomes 
affected growth and metastasis of the MCF-7 cells in zebrafish larvae, and also whether the 
liposomes associated, or accumulated close to the cancer cells. The results from the one test 
that was executed is displayed in Figure 5.23. Here MCF-7 cells were injected in the yolk sac 
and liposomes into the PCV. No interaction between the liposomes and cells were observed. 
This was expected since the liposomes will not be able to enter the yolk sac. The cells did not 
metastasize beyond the yolk sac, but the fluorescent events were observed to approximately 
double in both number and area (Table 5.6). One last experiment was attempted with yolk sac 
injections of MCF-7 and further injecting half of the recipients with free DOX in PCV, to study 
whether a therapeutic effect was observed. However, the test failed as cancer cells only were 
observed in three of the forty injected larvae, probably because the cancer cells clogged the 
microinjection pipette. Because of a limited number of recipients of MCF-7 cells in 
combination with DOX liposomes in the study, it cannot be concluded whether the liposomes 
















7 Conclusion and further work 
The cardioprotective effect of liposomal drug formulations intended for cancer therapy were 
tested on zebrafish larvae, and there was a clear cardioprotective effect observed from 
encapsulating DOX in liposomes. However, over longer periods of time the cardioprotective 
effect diminished, presumably due to degradation of the liposomes. This must be evaluated 
further in zebrafish larvae. The cell assays supported the theory of increased liposome toxicity 
over time, where high-dose SIM-DOX liposomes decreased viability of MCF-7 over 48 hours, 
while not after 24 hours. Whether this is due to the drug being released from liposomes into the 
cell medium, prolonged uptake by the cells or a delayed cytotoxic mechanism is not known.  
 
Additionally, the possible cardioprotective effect of SIM co-therapy with DOX treatment was 
explored. The cell assays showed increased viability of H9C2 cardiomyoblasts following 
exposure to high doses of free DOX and SIM compared to free DOX alone, indicating a 
cardioprotective effect of SIM co-treatment. In zebrafish larvae, however, a cardioprotective 
effect was not observed. The co-treatment appeared to give lower incidence of PCE in zebrafish 
larvae receiving DOX and SIM. These data can be improved by increasing the number of 
experiments to better establish the rate of PCE, and also by finding the optimal SIM-DOX ratio 
to verify this effect. Dose escalation tests of SIM liposomes should be conducted to find the 
MTD of SIM liposomes and also find the optimum SIM-DOX ratio for observation of a possible 
cardioprotective effect in zebrafish larvae.  
 
Zebrafish larvae were also tested as a model for cancer by utilizing xenograft transplantations 
of MCF-7 cells. The fluorescent signal used to stain the cells was observed to be present and to 
redistribute inside the zebrafish larvae, but more detailed microscopic analysis of the MCF-7 
injected recipients should be done to confirm the presence and movements of MCF-7 cells, and 
that the observed fluorescent signals were in fact viable cells metastasizing in the larvae. The 
effect of DOX liposomes were to be tested on MCF-7 injected zebrafish larvae, but due to 
limited laboratory time, no concluding results were achieved. However, during the work with 
this thesis, the necessary methods have been established, and preliminary experiments 
conducted of DOX-SIM toxicity and xenograft transplantations in zebrafish larvae, paving the 






Taken together, this study has demonstrated the power of the zebrafish model in toxicity of 
DOX and SIM, and as a cancer model for xenograft transplantations of MCF-7. Fluorescent 
signal from DiI and CTG stained MCF-7 cells was observed after injection of the cells in 
zebrafish larvae, but further experiments are required to confirm the presence and movement 
of live cancer cells. Liposomal DOX was observed to give less cardiac adverse effects than free 
DOX in zebrafish larvae, but the addition of SIM to the treatment did not provide further 
cardioprotective effects. Zebrafish larvae proves to be a more robust model than cells in 
revealing adverse effects of drugs, since toxic effects beyond cell death and proliferation can 
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Supplementary Figure 1: Heart contraction of untreated zebrafish larvae. The zebrafish 
larvae heart was for the heartrate toxicity assays filmed for ten seconds to calculate beats per 
minute. The zebrafish larvae were sedated in 0.2 mg/mL tricaine in embryo water and films 
obtained after placing the zebrafish larvae on an agarose gel. The images show the heartbeat 
of one zebrafish larva. A: A darker bolus of blood cells is observed in the zebrafish atrium. B: 
The blood has been pumped into the ventricle. C: The blood is pushed into circulation. Arrows 
point to the blood cell bolus. Still images captured from a film obtained using a Leica M205 







Supplementary Figure 2: Heart contraction of zebrafish larvae with pericardial effusion. The 
zebrafish larvae heart was filmed for ten seconds to calculate beats per minute. The zebrafish 
larvae were sedated in 0.2 mg/mL tricaine in embryo water and films obtained after placing 
the zebrafish larvae on an agarose gel. The images show the heartbeat of a zebrafish larva 
pretreated with doxorubicin, and suffering from pericardial effusion as a result. A and B: The 
atrium is filled up with blood cells. C: The blood cells have entered the ventricle. D: The blood 
is leaving the ventricle and entering the circulatory system. Still images obtained from a film, 







Supplementary Figure 3: WST-1 metabolic activity assay results from experiments with 
MCF-7 and H9C2 cells. After 24 hours incubation with DOX, SIM or both, as liposomes or as 
free drugs, the cells were added ten µL WST-1 and incubated for two hours at 37 °C. The 
absorbance of MCF-7 and H9C2 was measured at 450 nm. The results are displayed as the 
relative absorbance at 450 nm in the treated wells compared to the absorbance of the control 
wells with cells only incubated with cell medium. Some of the wells in the MCF-7 test (4.67 µM 
SIM free and liposomal, 5 µM DOX free and 1.51 µM SIM free drug wells) were by a mistake 

































































































































































Supplementary Figure 4: DiI stained MOLM-13 injected in zebrafish larvae yolk sac. DiI 
stained MOLM-13 acute myeloid leukemia cells were injected into the yolk sac of two days post 
fertilization zebrafish larvae and observed at one day post injection. The fluorescent signal was 
observed to be strong at one day post injection and was therefore also utilized to visualize 
MCF-7 cells. The images were obtained using Andor Dragonfly confocal microscope at 20x 








Supplementary Figure 5: DiI stained MCF-7 cells injected into the yolk sac of zebrafish 
larvae. Two zebrafish larvae injected with DiI stained MCF-7 cells in the yolk sac at two days 
post fertilization. A and D: Yolk sac visualized two to four hours post injection. B and E: Yolk 
sac visualized one day post injection. C and F: Yolk sac visualized two days post injection. The 
images were obtained using Andor Dragonfly confocal microscope at 10x magnification. Scale 










Supplementary Figure 6: CTG and DiI stained cell trackers injected into the posterior 
cardinal vein of zebrafish larve. A zebrafish larva injected with MCF-7 cells at two days post 
fertilization, stained with both DiI and CellTracker green. A: CTG is visible in a few cells at 
the day of injection. B: CTG stain not visible at one dpi, and only DiI stain observed. C: CTG 
stain not visible at two dpi, and only DiI stained observed. The images were obtained using 
Andor Dragonfly confocal microscope at 10x magnification. Scale bar: 200 µm.  
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